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ABSTRACT
MODELLING IN VITRO DISSOLUTION AND RELEASE OF SUMATRIPTAN
SUCCINATE FROM POLYVINYLPYRROLIDONE-BASED MICRONEEDLES
AIDED BY IONTOPHORESIS
by
James Paul Ronnander

A novel dissolving microneedle array system is developed to investigate permeation of a
sumatriptan succinate formulations through the skin aided by iontophoresis. Three
formulations consisting of hydrophilic, positively charged drug molecules encapsulated in
a water-soluble biologically suitable polymer, polyvinylpyrrolidone (PVP), have been
accepted by the U.S. Food and Drug Administration (FDA). The microneedle systems are
fabricated with 600 pyramid-shaped needles, each 500 µm tall, on a 0.785-cm2 circular
array. In vitro transdermal studies with minipig skin and vertical Franz diffusion cells show
> 68% permeation of sumatriptan over a 24-hour period. A combination of microneedle
and electrical current density ranging from 100 to 500 µA/cm2 using Ag / AgCl electrodes
displays increased flux with current density. At 500 µA/cm2, a dissolving array loaded with
4.3 mg sumatriptan leads to a steady-state delivery rate of 490 µg/cm2h with negligible lag
time. In theory, a 9.58-cm2 microneedle-array patch loaded with 47.30 mg of sumatriptan
succinate could provide the required plasma concentration, 72 ng/ml, for nearly six hours.
In parallel, a mathematical model based on first principles is developed to predict
the amount of drug delivered into the skin using software (e.g., Mathematica). A system of
mass balance equations are derived to simulate the dissolution, diffusion, electromigration
and transport of the active ingredient through the epidermis. The analytical approach allows
for the evaluation and estimation of the effects of key parameters (i.e., loading dose,

polymer concentration, needle height, needle pitch width and current density) on the
release profile. The skin layer concentration increases significantly with either increased
loading dose or elongated height of the microneedle. The percentage of sumatriptan
permeating through skin increased favorably with increased electrical current applied to
microneedle patch. An inverse correlation was observed between the pitch width (center to
center distance of adjacent needles) and the cumulative amount of sumatriptan permeated
into the dermis. Predicted cumulative release data from mathematical model simulations
of each of the three formulations were successfully validated with in vitro permeation data
administered with Franz cells and minipig skin.
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CHAPTER 1
INTRODUCTION
1.1

Objective

The goal of this dissertation is to help provide improved clinical results for large molecule
pharmaceutical products and biological drugs using minimally invasive transdermal
delivery systems. More specifically, this research focuses on the development of a
theoretical model based on transport phenomena principles to assess and predict drug
delivery of encapsulated sumatriptan succinate active pharmaceutical ingredients in
soluble microneedle systems alone and soluble microneedles aided by iontophoresis. The
theory-based approach has the potential for validating preliminary laboratory studies and
enhancing properties of the microneedle systems. Methods based on laboratory
experiments and mechanistic modeling will make the clinical research less risky, less
empirical and more reliable than trial-and-error experimental procedures.
In Chapter 2, materials and methods for development, the evaluation and in vitro
testing of the microneedle array systems are described. The micro array formulations are
analyzed to determine the best properties with respect to uniformity, strength, and
flexibility, and the ability to penetrate minipig skin. This step is critical because dissolving
microneedle arrays need to preserve uniformity in terms of needle array pattern, pitch
(space between needles), height and width. Test methods include: optical microscopy,
mechanical testing, and transepidermal water loss (TEWL). In vitro experiments with
vertical Franz diffusion cells measure the transdermal permeation of the active
pharmaceutical ingredient (API) across Göttingen minipig skin. Permeation experiments

1

are conducted with dissolving microneedles alone and aided by iontophoresis to enhance
penetration of drug molecules through the skin.
In Chapter 3, dissolving microneedle array systems are investigated as a suitable
alternative delivery method of sumatriptan for the relief of migraine. The formulations
consist of a positively-charged, encapsulated pharmaceutical ingredient (sumatriptan
succinate) and a hydrophilic, bio-compatible polymer (polyvinylpyrrolidone) approved by
the U.S. Food and Drug Administration (FDA). In vitro diffusion studies with Göttingen
minipig skins demonstrate an increase in drug release as compared to previously developed
sumatriptan transdermal patch systems. Further enhancement with electrical current
densities of 100, 300 and 500 µA/cm2 shows an increase in the steady-state flux of drug
with current density.
Finally, in Chapter 4, a mathematical model is developed to predict the in vitro
permeation of sumatriptan succinate molecules across the skin. Mass balance equations are
derived to detail the dissolution, diffusion, electromigration and transport of encapsulated
drug substance across the epidermis. A mathematical software (Mathematica®) is used to
solve the equations and derive relationships to predict the effects of critical parameters on
drug release. The computed (e.g., theoretical) release profiles were then validated with in
vitro diffusion studies using female minipig skin. The model successfully describes the in
vitro permeation of three distinct microneedle formulations containing sumatriptan.

1.2

Motivations

The oral administration of biological and pharmaceutical drug products is limited by poor
drug absorption and/or first pass effect metabolism in gastrointestinal (GI) tract or liver
[1-3]. The most common alternative is drug administration through subcutaneous/
2

intramuscular injections or intravenous infusion. However, the use of hypodermic needles
have several drawbacks, including the pain associated with injection. In addition, they are
difficult to administer, cost more and must be sterile. Another disadvantage is that these
drug delivery routes (except for intravenous infusion) lead to fluctuations in concentration
of drug in the blood plasma, a situation which can lead to toxic effects or ineffective
treatment [4].
This is the case with the drug sumatriptan succinate prescribed for the treatment of
acute migraines and cluster headaches. A triptan compound acts to bind serotonin (5hydroxytriptamine) receptors in the brain and induce vasoconstriction of arteries to reduce
neurogenic inflammation. Sumatriptan was the first available triptan compound and is
recognized as the leading standard in prescription migraine therapy [5-7]. Migraines affect
over 1 in 10 people globally, 31.8 % of patients experience three or more headaches per
month, and 53.7 % of migraine’s require bedrest due to severity [8, 9]. Migraine symptoms
typically include throbbing or pulsing pain, aura, sensitivity (light and sound), nausea and
vomiting [10-12]. There are several treatment options including various dosage forms
(intranasal spray, oral tablet, subcutaneous injection) but each method has limitations
which reduce patient compliance. For example, the oral and intranasal delivery routes
demonstrate lower therapeutic response (bioavailability 14% and 16%, respectively) and
may cause side effects (nausea and vomiting) [13, 14]. On the other hand, subcutaneous
injection is difficult for an individual to administer and may cause pain around the injection
site [15].
An attractive minimally invasive alternative is the use of transdermal systems
which can be self-administered and deliver a controlled amount of medication through the
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skin over an extended period of time (up to 7 days). These systems provide effective, painfree delivery of active ingredients into the bloodstream (avoiding first-pass metabolism
effects) with minimal side effects. A typical model of a transdermal therapeutic system
(TTS) is the matrix-controlled patch shown in Figure 1.1. The patch is comprised of an
occlusive backing layer, a drug-containing adhesive and a release liner. After removing the
release liner, the patch is applied to the skin for controlled release of the medication. The
drug must diffuse through the stratum corneum (10-20 µm thick) and the viable epidermis
(50-100 µm thick) to enter the capillary-rich dermis for systemic absorption. The primary
barrier is the stratum corneum comprised of “bricks” of corneocyte cells surrounded by a
“mortar” of intercellular lipid matrix of lipid bilayers. Typically, successful transdermal
drugs are low molecular weight compounds (< 500 Da), lipophilic (log P ~ 1 - 3), and
effective at low doses (few milligrams per day) [16-19]. Chemical permeation enhancers
can be added to formulations as excipients to reversibly disrupt the intracellular lipid
structures located in the stratum corneum and increase the permeation of large molecules.
The challenge is that the chemicals increase skin irritation and can damage deeper living
cells in dermal layers. Only a limited subset of chemical enhancers have been used to
successfully increase small molecule diffusion without skin irritation [20, 21].

Figure 1.1 Transdermal matrix-controlled system.
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Sumatriptan Succinate (C18H27N3O6S) has a molecular weight of 413.5 g/mol, is
freely soluble in water, hydrophilic (Log PpH 7.4 = -1.5), and has melting point of 165°C
making it ideal for aqueous formulations [22, 23]. However, previous in vitro studies by
Balaguer-Fernandez et al. demonstrate that standard transdermal methods, including
enhancers, are not suitable for the delivery of sumatriptan. A patch system comprised of
drug solution, methyl cellulose polymer and Azone® (enhancer) required a lag time of
15.21 h and surface area of 293 cm2 to achieve the target Cmax value of 72 ng/ml [24, 25].
Modern transdermal applications incorporate microneedle (MN) technology, or an
array of micron-sized needles in a small patch, designed to deliver macromolecules and
hydrophilic compounds through the skin. These microneedles effectively bypass the
stratum corneum and epidermis to achieve systemic drug uptake into the dermis. They are
designed with a pattern of micron-sized needles for perforation of the epidermis with
micron-sized ‘holes’, which create channels for drug delivery into dermal capillaries and
entry into the blood circulatory system. The individual microneedles are designed with
height in the range of 150 to 1,500 µm and a surface density less than 2000 needles/cm2.
These dimensions allow them to puncture the dermis without causing pain as they do not
penetrate into deeper skin layers to sever nerves and blood vessels. Several types of
microneedles (solid, coated, hollow and dissolving polymeric microneedles) have been
developed and investigated for different drug delivery applications. Solid microneedles are
used to enhance permeation of drugs through the skin by pre-treating an area of the skin
with microneedles prior to application of a transdermal formulation (i.e., ‘poke and patch’
method). Coated microneedles are coated with drug solution and inserted into the skin (i.e.,
‘coat and poke’ method). Hollow microneedles contain arrays of solid, hollow micron-
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sized needles filled with drug solution that is deposited directly into the dermis by diffusion
or pressure-driven flow (i.e., ‘poke and flow’ method). Dissolving microneedles are
fabricated with biodegradable polymers containing encapsulated active drug ingredients
which solubilize and are released into the skin [26-28].
Microneedle technology has been shown to greatly enhance in vitro and in vivo
transport of sumatriptan succinate drug across the skin. The ‘poke and patch’ method was
successfully utilized by Nalluri et al. (2015) for transdermal delivery of sumatriptan
through pig ear skin following pretreatment with Dermaroller® microneedle roller or
AdminPatch® solid microneedle patch. In vitro permeation results indicated that acceptable
therapeutic dose was possible with a 2.5 cm2 transdermal patch following pre-treatment
with an AdminPatch®, fitted with 1.5 mm length needles [29]. However, these solid,
stainless steel AdminPatch® microneedle systems are not disposable and considered
biohazardous sharps waste [30, 31]. Separately, two research groups developed dissolving
microneedles from polysaccharide polymers (sodium hyaluronate or dextran) for in vivo
delivery of sumatriptan succinate. In vivo studies for both polysaccharide microneedle
systems showed promising bioavailability (> 90%) compared to subcutaneous 6-mg
Imitrex® (sumatriptan) injection [32, 33]. Finally, a polyvinylpyrrolidone-based
microneedle device, ZP-Zolmitriptan, was developed by Kellerman et al. to deliver
zolmitriptan. Clinical phase I results showed ZP-Zolmitriptan achieved maximum blood
serum levels, and a Cmax value equal or greater than 2.5-mg oral dose of Zolmitriptan
[34].
The combination of iontophoresis and microneedle technologies has been shown to
have synergistic effects and increase uptake of macromolecules through the skin while
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modulating the drug delivery rate. Iontophoresis applies a low-density electric current (<
500 µA/cm2) to the skin to propel charged drug molecules through the low-resistance
tunnels created by the needles. For a positively charged drug, molecules are repelled by the
positive electrode (anode) and attracted to the negatively charged electrode (cathode) [16,
35-38]. Several in vivo and in vitro studies have demonstrated increased delivery of
macromolecules (oligonucleotides, dextrans, proteins) through porcine skin with
microneedle pre-treatment and iontophoresis as compared to iontophoresis alone [20].
However, research on the combination of dissolving microneedle and iontophoresis
technologies for drug administration is limited and neither method has influenced greatly
the transdermal drug delivery market.
The experimental portion of this research focused on i) developing dissolving
microneedles for the release of sumatriptan and ii) combining microneedle arrays with
iontophoresis to optimize delivery (Figure 1.2 and 1.3). Dissolving microneedles are
formulated from water-soluble biodegradable polymers that encapsulate the API within the
matrix. The dissolvable microneedles are inserted into the epidermis where they dissolve
in minutes, releasing the API into the dermis for rapid release into the systemic circulation.
Microneedles dissolve leaving no sharp medical waste for disposal after use and studies
show that skin punctures left by microneedles are painless and heal within 3 days [39-41].
There are several factors that affect drug delivery with microneedles, including
microneedle height, microneedle density, number of microneedles, drug concentration, and
size of encapsulated drug molecule [28, 39]. This research considered several sumatriptan
preparations to evaluate the formulations with respect to its strength, flexibility, uniformity,
and ease of insertion into the skin. These preparations were then combined with a range of
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current densities (100 – 500 µA/cm2) to determine the effect of the system on lag time,
steady-state diffusion flux and cumulative drug release. In vitro studies were conducted
with vertical Franz cells to determine sumatriptan release, from microneedle alone and
microneedle combined with iontophoresis, through Göttingen minipig skin [42].

Figure 1.2 Schematic representation of dissolvable microneedles for rapid release of
encapsulated drug.

Figure 1.3 Iontophoretic transdermal microneedle patch.
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Design optimization of the essential parameters of the microneedle systems is
paramount to improving drug delivery through the skin. The dissolving microneedle
systems must be able to properly insert into the skin without fracturing individual needles
in the array. Several physical properties effect microneedle insertion, including
microneedle geometry (shape of array), surface area, needle height, pitch width (center-tocenter distance of adjacent needles), and polymer matrix type. In 2004, a study by Davis et
al. demonstrated that the needle height and pitch-width were important properties with
long, densely packed arrays required for greater needle penetration into the skin [28, 43].
In 2008, Al-Qallaf et al. working with hollow or solid squared-shaped microneedle arrays,
developed a mathematical algorithm for determining the best parameters for the transport
of drug macromolecules across the skin. The study showed that the pitch width had a
greater impact on drug delivery than the needle radius [44]. In a separate study, Al-Qallaf
and Davidson et al. developed a mathematical model, based on Fick’s first law of diffusion,
to predict delivery of macromolecules from coated solid microneedles which confirmed
that needle height and pitch-width were crucial for increasing drug diffusion [45]. These
models are based on solid and hollow microneedle systems and cannot be applied to drug
delivery from dissolving microneedle arrays which involve dissolution and diffusion
processes.
In 2015, Kim et al. designed a system of dimensionless governing equations for
describing dissolution of an individual conical shaped microneedle and release of
encapsulated drug into a control volume. Several simulations were conducted with sucrose
microneedle containing encapsulated fentanyl citrate active substance that indicated i) a
decreased pitch led to an increased permeation and ii) the dissolution rate was independent
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of the elimination rate constant [46]. This research builds on previous studies by deriving
several mathematical models based on Nernst-Brunner equation, Fick’s 2nd law and
Coulomb’s law to describe: 1) dissolution of dissolving microneedles, 2) diffusion of drug
through the skin and 3) impact of iontophoresis on microneedle dissolution and drug
diffusion. Simulation experiments for each model allowed for a thorough analysis of the
impact of model parameters (e.g., drug load, needle height, needle pitch width and polymer
concentration) on the device performance. The predictions were then evaluated in the lab
with in vitro permeation experiments using Franz cells, excised Göttingen minipig skin
samples, and iontophoresis. Soluble microneedles with different formulations consisting
of PVP polymer and sumatriptan succinate API were tested to confirm the models.

1.3

Research Significance and Impact

This research focused on the development of theoretical models based on transport
phenomena principles to assess and predict drug delivery of encapsulated sumatriptan
succinate in soluble microneedle systems alone and soluble microneedles aided by
iontophoresis. The models were then used to identify critical attributes of the microneedle
system (i.e., microneedle height, base width, pitch width), formulation factors (i.e.,
concentration, solubility and density) and process parameters (i.e., current density). The
work was validated using in vivo permeation experiments with vertical Franz diffusion
cells and skin excised from female Göttingen minipigs.
The developed platform can help explain new experimental results, aid in product
design and the development of manufacturing processes. The contribution can be used to
evaluate the delivery of protein and peptide macromolecules, as well as, poorly soluble
drug molecules. The framework will potentially reduce R&D expenses, increase the quality
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of results and make the clinical research less risky, less empirical and more reliable than
trial-and-error experimental procedures.
The advantages of this research will be i) development of optimal transdermal drug
systems for the delivery of macromolecules to the systemic circulation, ii) more precise
prediction of drug delivery into the body, iii) reduction of therapeutic ‘lag time’ effect, and
iv) increased therapeutic effects of drug molecules.
The application and benefits of combining dissolved microneedles and
iontophoresis merit further analysis to unlock the full potential of this burgeoning
technology. A detailed assessment of the synergistic effects of the two methods promises
to result in a deeper understanding of design criteria pertinent to the transdermal delivery
of macromolecules. For example, many medical diseases and conditions require treatment
over a long period, e.g., from 24 hours to 7 days. For these cases, a slow and constant
supply of a macromolecule can be achieved by designing an iontophoretic transdermal
system with a slow dissolution of the microneedles. The current density is easily increased
to provide a faster release for patients requiring an immediate pain relief. It is possible to
adjust the device to design appropriate treatment regimens for specific patient groups and
drug molecules.
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CHAPTER 2
MATERIALS AND METHODS
2.1

Chemicals and Reagents

Microneedle formulations consisted of the active pharmaceutical ingredient (API)
sumatriptan

succinate

[3-[2-(dimethylamino)

ethyl]-N-methyl-indole-5-methane-

sulfonamide succinate (1:1)] purchased from Meohs Fine Chemicals (Iberica SL),
polyvinyl pyrrolidone (Kollidon K30) acquired from BASF (Ludwigshafen, Germany),
polysorbate 80 procured from Croda (New Castle, DE), and glycerine obtained from P&G
chemicals (Cincinnati, OH). All other chemicals and reagents were analytical grade.

2.2

Preparation of Sumatriptan Microneedle Arrays

The sumatriptan succinate microneedle systems were fabricated using methods previously
described by the author [42]. A total of four PVP-based sumatriptan microneedle
formulations were developed for characterization studies and their compositions are listed
in Table 2.1.
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Table 2.1 Microneedle Array Wet Composition (%, w/w)

Excipients

P1

P2

P3

P4

Sumatriptan

10

5

5

15

Polyvinylpyrrolidone

30

30

20

30

Water

58

63

73

53

Glycerine

1

1

1

1

Polysorbate 80

1

1

1

1

An aqueous pre-solution was prepared by slowly dissolving PVP, polysorbate 80
and glycerine in purified water, and degass by sitting on benchtop. The active solution was
formulated by adding an aliquot of this pre-solution (e.g., 2 – 5 ml) to a small beaker,
adding the sumatriptan succinate API, stirring until fully dissolved, and degas by sitting
un-stirred on the bench-top. Approximately 100 mg of active solution was pipetted into
each negative mold of platinum-cured silicone microneedle arrays (i.e., negative molds)
and pressed into microneedle chambers by pressure using methods described by other
research groups [47, 48]. The molds were dried at room temperature under ambient
conditions overnight on the lab bench. The dried microneedle arrays were carefully
removed from the PDMS molds and sealed in water-resistant containers. The PVPsumatriptan microarrays were stored in the sealed containers at room temperature for up to
6 weeks and retained their pyramid needle shape, as examined under microscope.
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These fabrication techniques were used to prepare circle microneedle arrays from
each preparation (P1 – P4 ) and square arrays from P1 formulation (Figure 2.1).

Figure 2.1 Photographs of P1 formulated dissolving microneedle arrays; A) circle array
containing 600 pyramid-shaped needles; B) square array containing 196 pyramid-shaped
needles.
2.3

Characterization of Microneedles with Light Microscope

The microneedle systems were visually examined using light microscope (Nikon Optishot2, Nikon, Japan), digital sight (Nikon D5-Fi1, Nikon, Japan) and imaging software (NISElements, Nikon, Japan) [42]. Circle microneedle arrays from each preparation (P1 – P4 )
and square arrays from P1 formulation were inspected to ensure they maintained consistent
appearance, shape and dimensions. Circle arrays from each formulation were inspected to
ensure they contained 600 uniform pyramid-shaped needles with consistent height of 500
µm, base width of 300 µm and pitch width (i.e., center-to-center distance between needles)
of 300 µm (Figures 3.4 – 3.7). Also, square-shaped arrays (P1 formulation) were examined
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to confirm each contained 196 individual pyramid-shaped needles with consistent height
of 500 µm, base width of 385 µm and pitch width of 700 µm.
A different optimal microscope (Swift-Duo, Vision Engineering, Woking, UK) and
imaging software (M3 Metrology, Vision Engineering, Woking, UK) were used to examine
minipig tissue samples following in vitro permeation trials. The minipig samples were
inspected for patterns of small holes corresponding to the circle and square microneedle
array patterns.

2.4

Tensile Strength

The microneedle systems mechanical strength was evaluated using a texture analyzer
(TA.XTPlus, Stable Microsystems Ltd, Godalming, UK), as described previously [42]. The
mechanical failure force of individual arrays was measured using the instrument in
compression mode equipped with a 3-point bend fixture (HPD/3 PB, Stable Microsystems
Ltd, Godalming, UK). Prior to performing the tests, the PVP-sumatriptan microneedles
were stored for 24 hours at 25 °C and 45% relative humidity for 24 hours. For each test, a
single microarray is loaded onto the 3-point bend fixture (Figure 2.1), a sensor probe
applied an axial load to the microneedle at 0.1 mm/s. The test was terminated when a
maximum displacement (5 mm) was attained or force decreased below a threshold (< 0.1
N). For each test, a force (N) versus displacement (mm) curve (similar to stress versus
strain curve), based on average force values (n=3), was generated.
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Figure 2.2 Set-up of three-point bend apparatus for testing mechanical strength of
microneedle array.
2.5

Mass, Drug Content and Density of Microneedle Systems

Laboratory experiments were conducted to determine the mass, drug content and density
of the microneedle systems. Ten microneedles, from each formulation, were prepared per
the methods described in Section 2.2. During preparation, the wet weight of drug solution
dispensed into each mold, mwet, and the dry weight of fabricated microneedles, mdry, were
measured on an analytical balance. The mass of the microneedle was calculated as the
average dry weight of the ten microneedles. The average drug content (i.e., mass fraction
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of sumatriptan API, β), in each microneedle was calculated using Eq. 3.1l; where

% Drug MN ,wet is the percent (%, w/w) of sumatriptan in the microneedle solution.

=

( % Drug ) ( m )
(m )
MN , wet

wet

(2.1)

dry

The density of the microneedle systems was measured by standard water displacement
technique described in [49]. A 5 ml aliquot of purified water was dispensed into a 10 ml
volumetric flask. The ten microneedles were inserted into the flask and submerged beneath
the surface of the water. The total volume of water was measured and used to calculate the
average density of the dissolving microneedles from each formulation.

2.6

Simulated Biological Fluid Preparation

A simulated biological solution was prepared, as previously described [49], as a surrogate
for interstitial fluid located in the skin. A one liter parenteral simulated body fluid,
developed by Marquis et. al. [50], was blended in the lab. The solution was determined to
be a suitable substitute for determining the solubility of the microneedle matrix polymer
(i.e., polyvinylpyrrolidone) in tissue fluid. The fluid was originally designed as a
dissolution medium for conducting experiments on parenteral dosage forms including
subcutaneous, intravenous, and intramuscular injections or implants.

2.7 Polyvinylpyrrolidone Solubility
The solubility of the matrix polymer (PVP) was measured in a simulated biological fluid
(solvent), as previously described by the author [49]. One hundred milliliter of simulated
biological solution was dispensed into a 250 ml glass beaker and stirred with a stand mixer
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(Eurostar, IKA, Staufen, Germany). PVP polymer was added to solution in increments of
10 g and allowed to dissolve into solution. The visual appearance was recorded and solution
viscosity was measured using a handheld Brookfield viscometer (Viscotester 2-plus,
Haake, Karlsruhe, Germany). The biological solution was determined to reach saturation
at 1.0 g/ml when the fluid viscosity exceeded that of lubricant oil (approximately 10 dPas).
It is presumed that the interstitial fluid viscosity would not exceed that of lubricant oil and
that this described a realistic solubility value. A plot of the viscosity (dPas) versus
concentration (g/ml) is shown in Figure 2.2.
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Figure 2.3 Viscosity – concentration curve for PVP in simulated biological fluid.
2.8 Minipig Skin Preparation
Whole female Göttingen minipig skin tissue samples (Ellegaard Göttingen Minipigs
Agricultural Service, Denmark) were purchased and prepared as described in [42]. Frozen
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full minipig skin samples were thawed at room temperature, rinsed with water, shaved to
remove hair and dermatomed to thickness of 800 µm (Acculan 3TI; Aesculap AG). The
prepared skin samples were punched into samples (25 mm diameter), frozen and stored for
use within a 9-month period. Göttingen minipig tissue was selected for the in vitro
permeation studies as an excellent model for human skin. The minipig skin is histologically
similar to human skin and exhibits lower inter- and intra-variation due to breeding
standardization [51, 52].

2.9

Optical Coherence Tomography Imaging

Optical coherence tomography (OCT) imaging equipment was used to generate highresolution, cross-sectional tomographic images of the Göttingen tissue structures in realtime during microneedle treatment. OCT imaging creates a set of 2-dimensional images
representing back-reflected light from a series of cross-sectional planes through the sample
[53]. In the lab, imaging was performed with an optical coherence tomography device
(VivoSight TP1302, Michelson Diagnostics Ltd., Kent, UK) and imaging software
(VivoSight 4.5 software, Michelson Diagnostics Ltd., Kent, UK). In vitro studies of
microneedle systems dissolving within the minipig tissue samples were imaged in realtime until needles were fully dissolved.

2.10 Transepidermal Water Loss (TEWL)
Transepidermal water loss (TEWL) was used to characterize the barrier function of the
minipig skin using a TEWL device (Biox AquaFlux, AF200, London, UK). The TEWL,
or skin surface vapor loss, is good indicator of the barrier function of the stratum corneum
with damaged skin (e.g., dry skin) displaying high TEWL values compared to normal skin
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[54-56]. Tests were conducted on mini-pig skin samples before and after insertion of
dissolving microarrays into the skin. Individual 10 mm diameter microneedles were
applied to a 25 mm diameter mini-pig skin samples. The microneedles were inserted using
a custom device which applied uniform tangential force across the skin (approximately 150
N/cm2). After insertion, the microneedle was held in-place on the skin for a period of 15
seconds to ensure good penetration into the skin surface. For comparison, TEWL was
measured before and after tape-stripping minipig skin 15x to remove the stratum corneum.
Tape-stripping skin 15x has been shown to remove horny corneocyte layers (stratum
corneum) from the epidermis [57]. The tape-stripping method involved applying a standard
pressure-sensitive adhesive tape (e.g., Scotch-tape®) to the skin surface, pressing firmly for
over 5 seconds and slowly remove tape.

2.11 In vitro Permeation Studies
In vitro diffusion experiments, as described previously [42], were performed in vertical
Franz diffusion cells (Glastechnik, Gräfenroda, Germany) with a diffusion area of 1.595
cm2. Frozen tissue samples (25 mm diameter) were thawed and placed with skin surface
(stratum corneum side) facing up on benchtop. To imitate realistic conditions, the tissue
samples were not pre-wetted. Sumatriptan microneedle arrays were placed gently onto the
skins and inserted into the skin using a custom applicator device designed to apply a
uniform impulse force (150 N/cm2) during insertion. The microneedle-skin samples were
covered with a PET liner and immediately placed into the Franz cells with the microneedles
facing the donor compartment. The occlusive PET liner was placed over the microneedleskin samples to facilitate diffusion into the skin. The receptor chamber was filled with 10mL phosphate buffer solution (pH 7.4) (PBS) containing sodium azide (0.1%, w/w), stirred,
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and controlled at 32 °C. At prearranged time intervals, the receiver cell solution was
withdrawn completely and replaced with fresh PBS (10 ml) to maintain sink conditions.
The diffusion studies were used to acquire data, including microneedle drug load (µg/cm2);
percentage drug released after 24 hours (%); cumulative amount of drug released after 24
hours, Q24h (µg/cm2); sumatriptan steady-state flux, Jss (µg/cm2/h); sumatriptan retained in
skin (µg/cm2) and lag time (h).
For comparison, passive diffusion (control) studies were conducted with inverted
microneedle samples from preparations P1 and P2. The control samples were prepared by
gently placing inverted microneedles (i.e., needles faced upward) onto minipig skin
samples, covered with occlusive PET liners and inserted into vertical Franz cell device.
Additional passive diffusion studies were performed with P1 and P2 microneedles on skin
samples after removing the skin’s stratum corneum. The stratum corneum was carefully
removed from the minipig skin samples using the tape-stripping method (15x) described
in Section 2.10. Following removal of the stratum corneum, inverted microneedles were
gently placed onto skins and covered with PET liners for placement in Franz cell. Finally,
in vitro permeation of a sumatriptan reference donor solution was measured. Reference
solution samples were prepared by applying 100 µl aliquot of 5 mg/ml sumatriptan
succinate in PBS (pH 7.4) solution to the non-woven pad (SA = 1.188 cm2) applied to the
skins (Figure 2.3), cover with PET liner and inserted into Franz cell.
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Figure 2.4 Non-woven pad on minipig skin containing sumatriptan reference solution.
For iontophoresis, in vitro permeation studies were set-up in a two chamber Franz
cell configuration with silver/ silver chloride electrode couples connected by a silver wires
(Figures 2.4 - 2.5). Sumatriptan succinate is positively (+) charged at pH 7.4, the anode
electrodes were placed in the donor compartment directly on-top of the microneedle-skin
samples [58]. A constant physiologically acceptable electric current, between 100 to 500
µA/cm2, was applied to microneedle-skin samples using a power supply (Hameg HM
7042-5, Mainhausen, Germany) [37, 59, 60]. The iontophoretic diffusion studies were used
to acquire data including: microneedle drug load (µg/cm2); percent drug permeated in 6
hours (%); cumulative amount after 6 h, Q6h (µg/cm2); sumatriptan steady-state flux, Jss
(µg/cm2/h); and lag time (h).
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Figure 2.5 Two-chamber franz cell system with electrical current.
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Figure 2.6 Two-chamber franz cell system with silver-silver chloride electrodes.
2.11 Analytical Methods
Analytical sample aliquots, collected from the receiver cell, were analyzed with a HighPerformance Liquid Chromatography (HPLC) system (Jasco LC-2000Plus Series, Tokyo,
Japan) [42]. The HPLC was equipped with a C18 column (Kromasil, 250 x 4.6 mm, 5 µm,
VDS Optilab, Berlin, Germany) and a UV Detector (Jasco 2077). The mobile phase
contained a mixture of sodium dihydrogen phosphate solution and acetonitrile (pH 3.2)
(90:10, v/v); flow rate of 1.5 ml/min. The UV detection set at 227 nm and the injection
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volume was 20 µL. The sumatriptan drug retained in the tissue samples after in vitro
diffusion were extracted by shaking samples in 5 ml methanol for 24 hours.

2.12 Statistical Methods
Statistical analysis was performed with Matlab software (Mathworks, Natick,
Massachusetts, US). An unpaired students t-test was applied to evaluate multiple data sets
using a one-way analysis of variance (ANOVA). The ANOVA comparison results were
considered statistically significant if p < 0.05.
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CHAPTER 3
DEVELOPMENT OF SOLUBLE MICRONEEDLE SYSTEM FOR DELIVERY
OF SUMATRIPTAN SUCCINATE
3.1

Formulation of Sumatriptan Dissolving Microneedle Array

For this research, a dissolving microneedle system was developed to meet several integral
design criteria including:
•

Microneedle is comprised of biocompatible polymer.

•

Microneedle is soluble in water.

•

Microneedle system has sufficient mechanical strength to penetrate skin.

•

Microneedle formulation is stable over long term storage at room temperature.

•

Active pharmaceutical ingredient is positively (+) charged at physiologic pH 7.4
for iontophoretic delivery.

•

Microneedle fabrication process is scalable for commercial manufacturing.

•

Microneedle device will meet regulatory compliance requirements.

These criteria were considered when selecting active and inactive pharmaceutical
excipients for the microneedle formulation.
A medium viscosity polyvinylpyrrolidone (Kollidon K30) polymer was chosen as
a binder due to its favorable properties that include readily soluble in water, inert, low
toxicity, biodegradeable, and biologically compatible [61]. Polyvinylpyrrolidone (PVP)
has been used in numerous oral tablet formulations as a binding agent and in ophthalmic
solutions as a lubricant. The polymer was approved by the FDA for use as an inactive
ingredient in pharmaceutical formulations [62]. Laboratory experiments confirmed PVP
(k30) readily dissolves in water at concentrations equal or less than 30% (w/w) and
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mixtures quickly degassed with slow mixing or standing still on lab bench. In contrast,
exploratory experiments with water-soluble carboxymethylcellulose (CMC) yielded
aerated, highly viscous solutions at low concentrations (< 5%, w/w) which could not be
degassed with a vacuum pump. For these reasons, PVP (k30) was selected as matrix
polymer for microneedle systems.
The active ingredient sumatriptan succinate (C18H27N3O6S) was selected as an
ideal active pharmaceutical ingredient for assessment of microneedle formulations.
Imitrex® (sumatriptan) is approved by the FDA for use in oral, subcutaneous, intranasal
and iontophoretic prescriptions [14, 25, 63, 64]. Sumatriptan has a molecular weight of
413.5 Da, an octanol/water partition coefficient of -1.5 (pH 7.4), a solubility in water of
101 mg/ml (20 °C), a low melting point of 165°C, and is positively charged. Thus, it is not
suitable for passive transdermal diffusion which requires small molecules with low
molecular weight (< 500 Da) and a high lipophilicity (Log P ~2-3) [18, 19]. However, a
well-designed microneedle device should be able to deliver large hydrophilic
macromolecules, such as sumatriptan, through the skin [28, 39]. Furthermore,
iontophoresis, or the application of a mild electric current (< 500 µA/cm2), has been shown
to significantly increase in vitro and in vivo transdermal delivery of sumatriptan succinate
[65, 66]. Thus, the sumatriptan succinate API will be used to evaluate microneedle
formulations for enhanced transdermal delivery with and without iontophoresis.
The excipient glycerin (i.e., glycerol) was added to the formulation as a lubricant
to provide smoothness to the microneedle systems. Preliminary formulations containing
PVP, sumatriptan and water resulted in microarrays that were difficult to remove from
silicone molds and often deformed during the de-molding process. Addition of 1% (w/w)
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glycerin to the formulations yielded smooth microneedle arrays that remained intact during
the demolding process (Figure 3.1b-e). The glycerin additive is frequently used in
pharmaceutical products with low risk of toxicity and accepted by the FDA as ‘generally
recognized as safe’ (GRAS).
The hydrophilic nonionic compound polysorbate 80 (PS 80) was incorporated as a
surfactant in the aqueous formulation. The PS 80 helped facilitate proper wetting of drug
solution onto the negative silicone molds by reducing surface beading effects. Additionally,
PS 80 increased the flexibility of the dried microneedle systems. Initial PVP, sumatriptan
and water formulated arrays yielded non-uniform, brittle microneedles with small air
bubbles (Figure 3.1a). Formulations with 1% (w/w) PS 80 provided uniform, flexible
microneedle systems that were bubble-free (Figure 3.1b-e). The PS 80 has been approved
by FDA for use in pharmaceutical and cosmetic industry in lotions, vaccines and
intravenous medications.
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Figure 3.1 Photographs of polyvinylpyrrolidone microneedle arrays; (A) microneedles,
containing only PVP (20%, w/w), are glassy, brittle, non-uniform and contain bubbles;
(B-C) microneedles, containing PVP (20%, w/w) , glycerol (1%, w/w) and polysorbate
80 (1%, w/w), are uniform, flexible and produce no bubbles; (D-E) P1 formulated
microneedles with sumatriptan are uniform, flexible and do show any bubble.
The formulations were made in the laboratory using standard mixing equipment.
Four different systems, with compositions described in Table 2.1, were prepared with
purified water, 5 – 15% (w/w) sumatriptan succinate, 10 – 20% (w/w) PVP, small amounts
of glycerin and polysorbate 80. A 50 ml pre-solution was prepared from inactive
ingredients in a beaker using a powered stand mixer. The pre-solution was easily degassed
with slow mixing or by standing still on the lab benchtop. A 2 – 5 ml active solution was
prepared by manually mixing sumatriptan powder with the pre-solution in a small beaker
using a metal spatula. The active solutions were degassed by allowing them to sit on a
benchtop. The sumatriptan API did not dissolve into solution at the higher 15% (w/w)
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concentration (P4 formulation) and tiny particulates were observed in the solution.
However, P4 microneedles were fabricated to assess the effects of increased drug load on
the physical properties of the microneedles, including needle geometry and mechanical
strength.
The circle and square-shaped microneedle arrays (Figure 2.1) were prepared from
the active solution using silicone molds (negative) and a small pressure vessel. The drug
solution was carefully pipetted into silicone molds which were then placed onto a custom
microneedle stand (Figure 3.2.b) for transfer into the pressure vessel (Figure 3.2.c). The
drug solution was filled into the needle cavities in the molds by applying 2 – 6 bar pressure
over the molds for approximately 15 minutes, similar to procedure described by Ripolin et
al. [47].
The molds were removed from the pressure vessel and dried overnight under
ambient conditions of 25 °C and 65% relative humidity (Figure 3.2.d). Following drying,
the microneedles were carefully peeled from the silicone molds and sealed in moisture
resistant containers. The microneedles were stored up to 6 weeks at room temperature and
individual needles retained their pyramid-shape, as verified by inspection under a
microscope.
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Figure 3.2 Photographs of the laboratory setup; (A) silicone mold filled with P1
solution; (B) stand to transfer filled microneedle molds into the pressure vessel;
(C) pressure vessel; (D) dried P1 microneedles in the silicone mold.

For commercial applications, regulatory agencies will probably require that the
microneedle devices be sterile and produced under aseptic conditions to prevent infection
during treatment. The previously described manufacturing process should be amended to
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sterile filter (0.22 µm) the active solution. The casting, drying and packaging operations
should be performed under aseptic conditions [67].

3.2

Characterization of Sumatriptan Dissolving Microneedle Array

The PVP-Sumatriptan dissolving microneedles were evaluated to determine the optimal
formulation (P1 – P4) in relation to a number of physical characteristics including:
•

Microneedle array uniformity.

•

Microneedle Drug Load, β

•

Microneedle Density, ρ

•

Solubility of PVP polymer in body fluid, cS

•

Microneedle mechanical strength

•

Microneedles ability to penetrate minipig skin

•

Transepidermal water loss (TEWL)

The microneedle formulations (P1 – P4) were evaluated with respect to uniformity,
strength, flexibility and ability to penetrate minipig tissues [42]. The microneedle systems
must maintain structural integrity with respect to needle array pattern, height, width, and
pitch width pre- and post- insertion for proper drug delivery. For example, an array with
non-uniform needle heights may lead to difficulty inserting the array into skin and/or
failure of some needles to penetrate the skin. Dissolving microneedle systems from each
formulation (P1 – P4) were visually inspected with a light microscope (Figures 3.3 – 3.7).
For each formulation, circular microneedle systems had a surface area of 0.785 cm2 and
contained a total of 600 needles with a height of 500 µm, width of 300 µm and pitch width
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of 350 µm. Square microneedle array systems were molded from P1 solution to form square
array patterns with a 0.884 cm2 surface area consisting of 196 needles with needle height
of 500 µm, needle width of 385 µm and pitch width of 700 µm. Table 3.1 contains a
summary of the geometric dimensions for each microneedle formulation, including the
microneedle surface area (SA), base width (w), height (h), needle pitch width (pw) and baseplate thickness (ɗbp). All microneedle formulations (P1 – P4) produced uniform
microneedle systems in terms of needle spacing, height, width and pitch width.

Figure 3.3 Optical microscope image P1 circle microneedle; (A) top-down view;
(B) side view.
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Figure 3.4 Optical microscope image P2 circle microneedle; (A) top-down view;
(B) side view.

Figure 3.5 Optical microscope image P3 circle microneedle; (A) top-down view;
(B) side view.
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Figure 3.6 Optical microscope image P4 circle microneedle; (A) top-down view;
(B) side view.

Figure 3.7 Optical microscope image P1 square microneedle; (A) top-down view;
(B) side view.

Laboratory experiments were performed to determine the physical properties of the
different microneedle formulations, including the microneedle dried mass (mdry),
microneedle drug load (β), microneedle density (ρ), and solubility of PVP in body fluid
(cS) (Table 3.1). The microneedle systems mass, drug content and density were calculated
using the methods described in Section 2.5, except for the P4 microneedles. The drug
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content and density of P4 microneedles were not measured due to the insolubility of
sumatriptan in the formulation. The arrays contained increasing drug content (β) in the
order of P2 < P3 < P1; with P1 micro arrays containing the most mass and drug content, as
expected, due to the higher PVP content and drug loading. The P1 square arrays had a
slightly higher drug content than circle arrays, which was attributed to a lower moisture
retention due to increased surface area. The most dense microneedle system was P3 with
array density decreasing in the order of P3 > P2 > P1. The determination of the solubility
of polyvinylpyrrolidone polymer matrix in simulated body fluid is described in Section 2.7.
The United States Pharmacopeia (USP) suggests the simulated biological fluid as a
dissolution medium for testing in vitro release rate of parenteral dosage forms including
subcutaneous, intravenous, and intramuscular injections [50].
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n = 600

n = 600

P3

P4

0.884

0.785

0.785

0.785

0.785

SA
(cm2)

0.0385

0.03

0.03

0.03

0.03

w
(µm)

0.05

0.05

0.05

0.05

0.05

0.07

0.035

0.035

0.035

0.035

ɗbp*
(µm)

NT

NT

0.019 ± 0.005

0.032 ± 0.002

0.038 ± 0.005

NT – not tested; N/A – not applicable; * Average values ± SD (n = 3)

P1

n = 196

n = 600

P2

Square Array

n = 600

P1

Circle Arrays

Needles

Needle
h
pw
(µm) (µm)

Geometric Dimensions

Table 3.1 Microneedle Dimensions and Physical Properties

66.6

46.4

25.8

36.3

40.2

mdry
(mg)

0.2256

N/A

0.1784

0.1234

0.2142

β
(%)

1.480

NT

1.291

1.210

1.150

ρ
(g/cm3)

1.0

1.0

1.0

1.0

1.0

cS
(g/cm3)

Formulation Properties

The mechanical strength of the dissolving microneedle formulations was measured using
a texture analyzer device. A 3-pt bend test was performed using the set-up depicted in
Figure 2.3. The 3-pt test was selected as means to evaluate both the strength and flexibility
of microneedle base-plate and individual needles. The microneedle base-plate and needles
require a certain degree of flexibility to prevent cracking during removal of systems from
the negative silicone molds. On the other hand, both the base-plate and individual needles
require strength to penetrate the skin’s surface during insertion without deforming or
breaking. The mechanical strength for each microneedle formulation was measured and
plotted in Force (N) – Displacement (mm) curves (comparable to stress-strain curves)
displayed in Figures 3.8 – 3.11. The Force-Displacement curves represent the average
mechanical strength (n = 3) of microneedles from each formulation (P1 – P4). The overall
force for all formulations (P1 – P4) started to decline after being displaced approximately
1.1 mm due to bending of the microneedle base-plate. Following mechanical testing, each
microneedle system was inspected under an optical microscope for system failures,
including cracks in the base-plate, deformed needles and/or broken needles. For all
formulations (P1 – P4), no cracks were observed in the base-plate and the individual
needles maintained a pyramid-shape with no observed deformations or broken needles.
The mechanical tests showed that increasing polymer concentration led to much stronger
microneedles and increasing drug content reduced microneedle strength. The results met
expectations as increasing polymer content increases the polymer lattice strength and
increasing the amount of API molecules in the formulation decreases the stability of the
polymer lattice.

For example, the P2 microneedles were prepared with the highest

concentration of polyvinylpyrrolidone polymer (30%, w/w) and lowest amount of
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sumatriptan succinate (5%, w/w) and exhibited the greatest maximum strength of 4.97 N.
Decreasing PVP concentration to 20% in P3 microneedles resulted in a drastic 42-fold
reduction in microneedle strength from 4.97 N to 0.12 N (p < 0.01). However, increasing
the microneedle sumatriptan load from 5 to 15% (w/w) with P4 microneedles yielded a
smaller 5-fold reduction in strength from 4.97 N to 0.90 N (p < 0.01).
The mechanical strength of square microneedles prepared from P1 solution were
tested and an average Force (N) – Displacement (mm) curve is plotted in Figure 3.12.
Following mechanical testing, the microneedle arrays were inspected under an optical
microscope and no cracks were observed in the base-plate and all needles maintained a
pyramid-shape with no deformations or cracks. The larger square microneedle showed
similar decline in peak force after being displaced approximately 1.1 mm. The square
arrays maximum peak force of 2.24 N was higher than the P1 circle array maximum force
of 1.63 N. The greater strength was attributed to the higher density (1.480 g/cm3) in the
square array as compared to the circle arrays (1.150 g/cm3).
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Figure 3.8 Mechanical test (3-pt bend) of P1 microneedles (circle); average values
(n = 3).

Figure 3.9 Mechanical test (3-pt bend) of P2 microneedles (circle); average values
(n = 3).
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Figure 3.10 Mechanical test (3-pt bend) of P3 microneedles (circle); average values
(n = 3).

Figure 3.11 Mechanical test (3-pt bend) of P4 microneedles (circle); average values
(n = 3).
41

Figure 3.12 Mechanical test (3-pt bend) of P1 microneedles (square); average values
(n = 3).
During in-vitro trials the minipig skin samples were examined to assess the
microneedles ability to puncture and penetrate the skins surface. Microscopic images of
the skin samples post-treatment were taken and visually confirmed the needles successfully
punctured the skin (Figure 3.13). In addition, an indicator solution (nitrazine yellow dye)
was applied to minipig skin following treatment to increase visibility of the skin punctures.
The dye turned the minipig skin blue allowing for quick visual inspection of minipig skins
un-aided by the microscope. An inspection of minipig skin confirmed successful
penetration of circle arrays (P1 – P3) and square arrays (P1) (Figure 3.14).
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Figure 3.13 Optimal microscope images; (A) blank minipig tissue (10x mag);
(B) minipig tissue post-treatment with P1 microneedle (10x mag); (C) minipig tissue
post-treatment with P1 microneedle (50x mag).
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Figure 3.14 Photographic images of minipig tissue stained with nitrazine yellow dye;
(A) blank minipig tissue; (B) P1 circle array treated minipig tissue; (C) P2 circle array
treated minipig tissue; (D) P3 circle array treated minipig tissue; (E) P1 square array
treated minipig tissue.
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In vitro optical coherence tomography (OCT) study was used to observe and
evaluate the microneedle systems solubilize and dissolve within the skin. The OCT
imaging system was capable of generating micron-scale, high resolution 2-D crosssectional images of the needles within the tissue samples [68, 69]. Figure 3.15 displays
images of P1 formulated microneedles dissolving in dermatome (800 µm) female
Göttingen minipig skin over a ten minute period. The images confirm the PVP-based
needles rapidly dissolve immediately following insertion into the moist skin. Following 10
minutes, the individual needles were completely solubilized and the microneedle baseplate had begun to dissolve.
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Figure 3.15 Optical coherence tomographic images of P1 circle microneedle dissolving
in minipig tissue over time; dissolution of microneedle at (A) 1 min; (B) 2 min;
(C) 4 min; (D) 10 min.
The skin barrier function was characterized by measuring transepidermal water loss
(TEWL) of minipig skin pre-and post- treatment with dissolving microneedles. TEWL, or
measurement of skin surface vapor loss, is an effective tool for determining the integrity
of the stratum corneum (i.e., skin barrier). Damaged skin (i.e., dry skin) is unable to retain
moisture and will result in higher TEWL values [54, 55, 70]. TEWL measurements were
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taken before and after application of microneedles (circle) into the skin for 15 seconds
(Table 3.2). Following treatment of skin with the P1 microneedle arrays, the minipig skin
surface average water loss increased 4.9-fold (p < 0.001). The increased evaporation is
explained by the array of micron-scale tunnels present in the skin after microneedle
treatment which create low resistance pathways for transport of water through the skin. A
similar 4.6-fold increase in average TEWL was realized after removing the stratum
corneum from the skin utilizing the tape-stripping technique (15x) (p < 0.001). A
comparison of the TEWL values for skin treated with P1 circle microneedles versus skin
treated by tape-stripping method showed no significant differences (p > 0.05). These results
indicate the circle microneedle arrays effectively bypass the stratum corneum.
Table 3.2 TEWL Values of Minipig Skin Pre- and Post- Microneedle Treatment or
Tape-Striping Technique (15x); Average Values ± SD

Minipig
Lot

Sample
Size

Insertion
Time (sec)

TEWL
(g/m2/h)

Difference
(g/m2/h)

Control (no microneedle)

325975

n=3

15

15.18 ± 2.92

N/A

P1 Microneedle

325975

n=3

15

73.86 ± 0.36

58.68 ± 2.70

Control (no tape-strip)

325975

n=3

15

15.36 ± 1.21

N/A

Tape-strip (15x)

325975

n=3

15

70.41 ± 3.56

55.05 ± 2.38

Sample

Circle Microneedle

Tape-Stripping

An overall comparison of the physical characteristics of the four formulations (P1
– P4) and array types (circle & square) indicates the optimal dissolving microneedle system
is a P1 formulated circle microneedle. The P1 formulation contains optimal sumatriptan
API drug loading (10%, w/w), highest possible PVP-polymer content (20%, w/w), good
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mechanical properties and inserts well into minipig tissue. The other three formulations
were sub-optimal for various reasons: P4 formulation contained undissolved sumatriptan
API, P2 and P3 formulations contained lower drug load. The circle and square arrays both
penetrated the minipig skin, but the circle array is preferred as it contains a denser array
pattern with over three times the number of individual needles in a smaller surface area.

3.3

In vitro Diffusion of Sumatriptan Microneedles Using Minipig Skin Model

In vitro permeation studies to determine drug release of sumatriptan succinate through
minipig skin were executed with circle microneedle arrays from three of the formulations
(P1 – P3) [42]. Permeation trials were carried out using vertical Franz diffusion cells with
female Göttingen minipig tissue as a suitable and preferred model for in vitro diffusion
through human skin. The minipig skin has been shown to exhibit lower intra-donor
variation compared to human skin due to variations in the human skin age of donors and
lifestyles [51, 71]. Each of the minipig skin samples was shaved to remove hair on skin,
dermatomed to 800 µm thickness and skin surface was gently dried. A tissue sample
thickness of 800 µm was selected to ensure the 500 µm needles in the microneedle systems
did not pierce through skin releasing drug directly into the receiver compartment. The toplayer skin surface was carefully dried and not pre-wetted to mimic realistic conditions for
microneedle treatment. A detailed description of the minipig skin preparation is described
in Section 2.8. The permeation trials were carried out over 32 hour period with samples
collected at 1, 2, 6, 8, 24, and 32 hours. During each interval the receiver cell solution was
completely emptied and replaced with phosphate buffer solution to maintain sink
conditions. The in vitro minipig permeation trial lab set-up and test condition specifics are
outlined in Section 2.11.
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The permeation trials included transdermal diffusion experiments with dissolving
microneedles, passive diffusion (control) experiments, passive diffusion experiments
following removal of stratum corneum and a sumatriptan succinate reference solution
(Figures 3.16 – 3.19). The dissolving microneedle experiments were performed with
microarrays inserted into minipig skins and placed into Franz cells with the needles facing
the donor compartment. Passive diffusion (control) tests were conducted with P1 and P2
arrays by inverting the microneedles on the skin samples (i.e., needles facing up) to mimic
application of a traditional transdermal patch. Additional passive diffusion experiments
were carried out with inverted P1 and P2 microneedles on minipig skin after removal of
the stratum corneum using the tape-stripping technique (15x). Finally, the permeation of a
sumatriptan succinate reference solution was evaluated which comprised 5 mg/ml
sumatriptan API in phosphate buffer solution (pH 7.4). At the completion of each trial, skin
samples were visually inspected with blue dye solution (nitrazine blue dye) to ensure
microneedles fully dissolved and the full array penetrated the skin.
Results, included microneedle drug load (µg/cm2); percentage drug released after
24 hours (%); cumulative amount of drug released after 24 hours, Q24 (µg/cm2);
sumatriptan steady-state flux, JSS (µg/cm2/h); lag time (h), and sumatriptan API retained in
skin (µg/cm2). The steady-state flux was determined by calculating the slope of the steadystate part of the cumulative flux curves. The steady-state flux was reached between 2 – 8
hours for microneedle systems, between 24 – 32 hours for control samples, between 2 – 8
hours for tape-stripped control samples, and 24 – 32 hours for reference samples. All in
vitro results are summarized in Table 3.3 and cumulative flux curves are contained in
Figures 3.16 – 3.19.
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Circle microneedle arrays from each of the three formulations P1, P2 and P3
successfully released over 26% sumatriptan API after eight hours (average, n = 3), over
68% sumatriptan API after twenty-four hours (average, n = 3) and over 82% after thirtytwo hours (average, n = 3). A linear relationship was observed between loading of
sumatriptan succinate in microneedles versus cumulative drug release at 24 hour and
steady-state flux. For example, a 2-fold increase in drug load from 5 – 10% (w/w) related
to 2-fold increase in the cumulative drug release and steady-state flux. This is observed
when comparing the P1 circular microneedles (10% w/w sumatriptan, Q24h = 7598 µg/cm2;
Jss = 395 µg/cm2/h); with either the P2 circular microneedles (5% w/w sumatriptan, Q24h =
4059 µg/cm2; Jss = 192 µg/cm2/h; p < 0.001) or P3 circular microneedles (5% w/w
sumatriptan, Q24h = 4291 µg/cm2; Jss = 268 µg/cm2 h; p < 0.001). Increasing the
polyvinylpyrrolidone polymer content from 10 to 20% (w/w) in P2 circle arrays versus P3
circle arrays had no effect on drug release (p > 0.05) and a slight decrease in steady-state
flux (p < 0.05). Circle microneedle arrays from each of the formulations exhibited quick
release with lag times < 40 minutes. For all three formulations, over 85% sumatriptan
succinate API was accounted for in the receiver cell aliquots and retained in minipig skin
post-testing.
Control experiments were performed with circle-shaped microneedles (P1 and P2)
as a means to evaluate the effectiveness of dissolving microneedle systems. The P1 and P2
control samples exhibited a higher degree of variability between samples (SD > 70%) and
significantly lower drug release at 24 hour (p < 0.05) and steady-state flux (p < 0.001), as
compared to the microneedle samples. Furthermore, the release was extremely slow with
lag times of 6 hours and 9. 4 hours for P1 and P2 control samples, respectively. This data
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demonstrates the circle-shaped dissolving microneedle arrays are a very effective active
transdermal system for transporting sumatriptan through the epidermis.
The circular microneedles ability to completely bypass the skin’s stratum corneum
(i.e., primary barrier) was tested by placing inverted microneedles (similar to control test)
on tissue samples after the stratum corneum was removed tape-stripping (15x). The
inverted microneedles (P1 and P2) on tape-stripped skin released over 24% sumatriptan
API after eight hours (average, n = 3), over 54% sumatriptan API after twenty-four hours
(average, n = 3) and over 64% after thirty-two hours (average, n =3). For P1 and P2
microneedles, no significant differences were observed between drug release at 24 hours
(p > 0.5) and steady-state flux (p > 0.5), as compared to the inverted microneedles on tapestripped skin. These results prove the microneedles effectively bypass the stratum corneum
for drug delivery directly into the dermal layers of the skin. The arrays have needles with
length of 500 µm which penetrates through the stratum corneum (approximately 50 µm)
and deep into the epidermal layers of the skin. This creates deep channels for solubilized
sumatriptan drug to transport through the skin.
Review of the in vitro microneedle data from the three formulations (P1 – P3)
indicates the optimal microneedle system is a P1 formulated circle microneedle array. The
P1 formulation contains the maximum amount of sumatriptan API (10%, w/w) which
related to the highest drug release. However, results show that the PVP concentration
should be reduced to (20%, w/w) which would lead to increased steady-state flux of
sumatriptan.
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3.4 In vitro Delivery of Sumatriptan From Dissolving Microneedle Arrays Aided
by Iontophoresis
Iontophoresis in vitro studies were carried out to enhance the transdermal delivery of the
positively-charged sumatriptan succinate molecules through the skin. In vitro tests
included:
•

Visual examination of microneedle and iontophoresis treated minipig skin.

•

Transepidermal water loss (TEWL) of microneedle and iontophoresis treated
minipig skin.

•

In vitro Franz cell permeation studies with iontophoresis.

The in vitro experiments involved insertion of microneedle arrays into Göttingen minipig
skin and applying a mild, constant electrical current, 100 to 500 µA/cm2, across the samples
during diffusion. Tests included circle-shaped microneedle arrays formulated from P1, P2
and P3 solulation, as well as, square-shaped microneedle arrays formulated from P1
solution. Permeation trials were implemented over a six-hour period with samples
extracted at 1, 2, 3, 4, and 6 hours. Sink conditions were maintained by completely
emptying and refilling the Franz receiver cell following each interval. The six-hour
treatment time was selected as comparable to the Zecuity® iontophoretic device approved
by the FDA for transdermal delivery of sumatriptan succinate over four hours [35, 72]. The
in vitro iontophoretic diffusion trial lab set-up and test conditions are described in detail in
Section 2.11.
In vitro studies included experiments with dissolving microneedles aided by
iontophoresis, dissolving microneedles un-aided by iontophoresis, and passive diffusion
(control) experiments. Tests involving dissolving microneedles were conducted with
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individual circle or square microarrays inserted into minipig skins and placed into Franz
cells with the microneedles facing the donor compartment.. The passive diffusion (control)
tests were conducted by inverting microneedle arrays on top of the minipig skin (i.e.,
needles facing up) to simulate passive transdermal delivery from these systems.
At the completion of each trial, skin samples were visually inspected with blue dye
solution (nitrazine yellow) to verify microneedles pierced the skin and were fully dissolved.
For circle arrays (P1 – P3) and square arrays (P1), a recognizable circle or square pattern
was visible in the skin samples. Applying increasing electrical current made the patterns
darker and more distinct with the higher current density (500 µA/cm2) being the most
pronounced. This is observed in Figure 3.20 which contains photographs of the blue dyed
tissue samples following in vitro testing with and without iontophoresis.
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Figure 3.20 Photographic images of minipig tissue dyed with nitrazine yellow dye; (A)
blank minipig tissue; (B) P1 circle microneedle; (C) P1 circle microneedle with
100 µA/cm2; (D) P1 circle microneedle with 500 µA/cm2.
TEWL values were used to assess iontophoretic microneedle treatments effect on
skin barrier functionality for both circle and square microneedle arrays. TEWL
measurements were taken before and after six-hour in vitro permeation trials with control
samples, dissolving microneedle samples and dissolving microneedle samples with
electrical current (Table 3.4). For circle microneedle arrays without iontophoresis, the
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average TEWL measurements increased 2.6-fold for minipig samples treated\using P1
circle micro arrays (p < 0.001), 3.1-fold for P2 micro arrays (p < 0.001), and 3.1-fold for
P3 micro arrays (p < 0.001). The addition of a high electric current (500 µA/cm2) across
samples during the six-hour diffusion period correlated to minor increases in TEWL values.
For minipig skin treated with P1, P2 and P3 circle microneedles and iontophoresis, the
average TEWL increased 2.7-fold (p < 0.001), 3.1-fold (p < 0.001) and 3.3-fold (p < 0.001),
respectively. For P1 and P2 microneedles, no significant difference was observed between
microneedles with or without iontophoresis (p > 0.5). However, for P3 microneedles a
significant difference was observed (p < 0.01). The results indicate that iontophoresis has
an increased effect on microneedle arrays containing less polymer. The square
microneedles formulated from P1 solution resulted in a 2.6-fold increase in average TEWL
values (p < 0.001). Testing with a high electrical current (500 µA/cm2) electric current
resulted in slightly larger average TEWL values exhibiting a 3.2-fold increase which were
not significantly different from non-iontophoresis results (p > 0.05).
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Table 3.4 TEWL Values of Minipig Skin Pre- and Post- Microneedle Treatment or
Microneedle Treatment Aided by Iontophoresis; Average Values ± SD

Sample

Minipig
Lot

Sample
Size

Insertion
Time (h)

TEWL
(g/m2/h)

Difference
(g/m2/h)

Control (no microneedle)

228932

n=3

0

25.46 ± 4.69

N/A

Microneedle

228932

n=3

6

65.24 ± 3.49

39.78 ± 5.00

Microneedle + 500 µA/cm2

228932

n=3

6

69.52 ± 5.69

44.07 ± 4.26

Control (no microneedle)

229025

n=3

0

21.82 ± 2.22

N/A

Microneedle

229025

n=3

6

67.59 ± 3.57

45.76 ± 4.53

Microneedle + 500 µA/cm2

229025

n=3

6

68.28 ± 2.66

46.46 ± 4.51

Control (no microneedle)

229025

n=3

0

21.00 ± 3.20

N/A

Microneedle

229025

n=3

6

64.94 ± 1.06

43.94 ± 3.97

Microneedle + 500 µA/cm2

229025

n=3

6

68.60 ± 0.40

47.60 ± 2.89

Control (no microneedle)

231545

n=3

0

20.57 ± 1.48

N/A

Microneedle

231545

n=3

6

54.21 ± 4.88

33.64 ± 4.88

Microneedle + 500 µA/cm2

231545

n=3

6

65.59 ± 4.11

45.48 ± 3.12

P1 Circle Array

P2 Circle Microneedle

P3 Circle Microneedle

P1 Square Microneedle

In vitro permeation data, including microneedle drug loading (µg/cm2); percentage
drug released at six-hours (%); cumulative amount drug released at six-hours, Q6 (µg/cm2);
steady-state flux, JSS (µg/cm2/h); and lag time (h). The steady-state flux and lag time were
determined from the slope of the steady-state portion of the cumulative flux curves between
2 – 6 h. For control samples, the steady-state flux and lag time were not calculated as the
steady-state portion of the cumulative flux curves occurred between 24 – 32 h, see
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Section 3.4. All in vitro results are summarized in Table 3.5 and cumulative flux curves
are contained in Figures 3.21 – 3.25.
The circle dissolving arrays from the three formulations (P1 – P3) each successfully
released over 953 µg/cm2 after six hours (average, n = 3). The lag time for microneedles to
reach steady-state flux varied from 30 – 60 minutes for all microneedle samples. A
relationship was not observed between increased drug loading and either cumulative drug
release or steady-state flux. For example, increasing drug load 2-fold from 5 to 10% (w/w)
and keeping PVP concentration constant at 30% (w/w) led to negligible increases in the
cumulative drug release and steady-state flux. This is observed in comparing P2 circular
microneedles (Q6h = 953 µg/cm2; Jss = 184 µg/cm2/h) to P1 circular microneedles (Q6h =
1133 µg/cm2; Jss = 206 µg/cm2/h); p > 0.05). Doubling the drug load and increasing
polymer concentration from P3 (Q6h = 1050 µg/cm2; Jss = 226 µg/cm2/h) to P1 (p > 0.5) led
to insignificant changes in cumulative drug release and steady-state flux. And a 10% (w/w)
higher concentration in PVP polymer between P3 and P2 did not have a significant impact
on drug release or steady-state flux (p > 0.5). That said, the cumulative drug release of
sumatriptan from control samples at six hours was 23 – 51% lower than their dissolving
microneedle counterparts. This confirms the effectiveness of the microneedle arrays in
circumventing the stratum corneum to deliver drug within the dermis versus passive
transdermal diffusion.
Addition of an electrical current of 500 µA/cm2 resulted in 149% increase in drug
release at six hours for P3 microneedles, 95.2% increase for P1 microneedles and 50.6%
increase for P2 microneedles. The P3 formulated microneedle aided by iontophoresis
demonstrated no lag time, but the P1 and P2 had lag times between 36 and 54 minutes.
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Increasing the polymer matrix concentration from 20 – 30% (w/w) while maintaining
constant drug load resulted in approximate 2-fold increase drug release and steady-state
flux values. This was demonstrated between the P2 microneedles (Q6h = 1437 µg/cm2;
Jss = 266 µg/cm2/h) with under 500 µA/cm2 electrical current in comparison to P3
microneedles (Q6h = 2888 µg/cm2; Jss = 490 µg/cm2/h, p < 0.01). Doubling the sumatriptan
succinate load between P2 and P1 (Q6h = 2262 µg/cm2; Jss = 433 µg/cm2/h, p < 0.05)
increased drug release and steady-state diffusion by > 57%.
Square microneedle arrays formulated from P1 solution and loaded with 17.04
mg/cm2 sumatriptan demonstrated a cumulative release of 258 µg/cm2 and steady-state
diffusion of 49 µg/cm2/h after six hours. The results were disappointing as drug release
was 22.8% lower than a P1 formulated circle array loaded with less sumatriptan succinate
(10.8 mg/cm2). Combining the P1 square microneedles (Q6h = 258 µg/cm2;
Jss = 49 µg/cm2/h) with 500 µA/cm2 electrical current significantly increased drug release
327% and steady-state diffusion 279% (Q6h = 1102 µg/cm2; Jss = 186 µg/cm2/h, p > 0.01).
The higher electrical current was able to increase flux of charged molecules and
compensate for the square microarrays reduced ability to bypass stratum corneum.
The results of in vitro microneedle testing with iontophoresis for the three
formulations (P1 – P3) demonstrate the most suitable microneedle device as a P3
formulated circle microneedle array. The P3 formulation contained minimal sumatriptan
succinate (5%, w/w) but released 27% more drug than P1 microneedle with double the
amount of API when combined with 500 µA/cm2 electrical current. The higher drug load
is attributed to reduced polymer matrix in formulation P3 which allows for faster diffusion
of charged molecules into epidermis by iontophoresis and no lag time. These results
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indicate an optimal iontophoretic microneedle device would contain 10% (w/w)
sumatriptan succinate and 20% (w/w/) polyvinylpyrrolidone which should lead to even
greater drug release and higher steady-state flux values.
Table 3.5 Franz Cell In vitro Permeation Data for Sumatriptan Succinate Through
Minipig Skin After Six Hours Aided by Iontophoresis; Average Values ± SD

Sample
Size

Drug Load
(µg/cm2)

Cumulative
Drug
Released, Q6h
(µg/cm2)

Percentage
Drug
Released, Q24h
(%)

Steadystate Flux,
JSS
(µg/cm2/h)

Lag
Time
(h)

P1 (Control)

n=3

10679 ± 206

579 ± 396

5.5 ± 3.8

N/A

N/A

P1 MN

n=3

10773 ± 285

1133 ± 259

10.5 ± 2.5

206 ± 49

0.5 ± 0.7

P1 MN + 100
µA/cm2

n=3

10887 ± 128

1362 ± 311

12.5 ± 2.9

267 ± 63

1.0 ± 0.1

P1 MN + 300
µA/cm2

n=3

10913 ± 159

1132 ± 193

10.4 ± 1.7

208 ± 43

0.6 ± 0.1

P1 MN + 500
µA/cm2

n=3

11062 ± 110

2262 ± 437

20.5 ± 4.0

433 ± 74

0.9 ± 0.1

P2 (Control)

n=3

5380 ± 162

223 ± 237

4.2 ± 4.5

N/A

N/A

P2 MN

n=3

5361 ± 87

953 ± 233

17.8 ± 4.1

184 ± 42

0.9 ± 0.2

P2 MN + 500
µA/cm2

n=3

5369 ± 121

1437 ± 163

26.8 ± 2.9

266 ± 23

0.6 ± 0.3

P3 (Control)

n=3

5416 ± 135

243 ± 124

4.5 ± 2.4

N/A

N/A

P3 MN

n=3

5367 ± 131

1050 ± 332

21.4 ± 6.2

226 ± 62

1.0 ± 0.2

p3 MN + 500
µA/cm2

n=3

5437 ± 89

2888 ± 350

53.2 ± 7.3

490 ± 17

0.0 ± 0.7

P1 (Control)

n=3

17048 ± 346

64 ± 62

0.4 ± 0.4

N/A

N/A

P1 MN

n=3

17040 ± 458

258 ± 89

1.5 ± 0.5

49 ± 28

0.3 ± 1.3

p1 MN + 500
µA/cm2

n=3

17131 ± 173

1102 ± 668

6.5 ± 4.0

186 ± 110

0.1 ± 0.1

Sample

Circle Arrays

Square Arrays
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3.5

Transdermal Microneedle Devices for Drug Delivery of Sumatriptan Succinate
With and Without Iontophoresis

The rate of sumatriptan succinate drug delivery to patients from the proposed microneedle
device and iontophoretic microneedle device were determined using a one-compartment
pharmacokinetic model. The one-compartment model was evaluated using microneedle in
vitro flux data and clinical trial data for sumatriptan succinate 6-mg subcutaneous injection
(Imitrex®) reported in the literature [73]. The following clinical study parameters and
assumptions were used to develop the one-compartment model,
•

Drug administered at a constant zero-order infusion rate, R

•

Drug eliminated by first-order process

•

Mean plasma concentration, Cmax = 72 ng/ml

•

Volume of distribution, VD = 170 L

•

Drug elimination half-life, t1/2 = 2 h

The mass balance for slow, constant infusion (zero-order rate) of drug substance
and elimination (first-order rate) is given by Equation 3.1, with drug in the body, DB;
infusion rate, R; and elimination rate, kEL.

dDB
= R − k EL DB
dt

(3.1)

The concentration of drug in the body is written in terms of the plasma drug
concentration, CB, and volume of distribution, VD; (i.e.,
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DB = CBVD )

VB

dCB
= R − kEL CBVD
dt

(3.2)

Applying the steady-state approximation, Equation 3.2 is reduced to

R = kELVDCB*

(3.3)

*

Where CB represents the steady-state drug plasma concentration (i.e., Cmax). The
elimination rate can be was determined from its relationship to the drug half-life per
Equation 3.4

t1/2 =

0.693
kEL

(3.4)

Applying sumatriptan clinical data for the volume of distribution (VD = 170 L) and
half-life (2 h) reveals the microneedle device must delivery an infusion rate of 4.24 mg/h
to maintain the target plasma levels (Cmax = 72 ng/ml).
3.5.1 Sumatriptan Dissolving Microneedle Device Design
The in vitro results for P1 formulated dissolving microneedles (Section 3.3) demonstrated
a mean steady-state flux of 395 μg/cm2 over a 7 h period and lag time of approximately 39
minutes. Hypothetically, a dissolving microarray patch with area of 10.7 cm2 and 118.8 mg
sumatriptan could provide therapeutic relief (i.e., 72 ng/ml) from migraines over a 7 hour
period. This is a significant improvement when compared to previous studies for
development of a sumatriptan transdermal patch. A traditional sumatriptan patch
formulated with methyl cellulose polymer and Azone® enhancer would require a 15 hour
lag time and 293 cm2 patch area [24].
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It is suggested that a smaller sumatriptan microarray patch is designed by reducing
the PVP content in the system which was shown to increase the in vitro steady-state drug
flux. The patch should be modified to include an adhesive backing layer over the system
for adhering the patch to the skin. A separate applicator device will be used by the patient
to insert the microarray device into the patients skin. Once inserted into the skin, the patch
would require a thirty minute application period for the microneedles to dissolve into the
skin.
3.5.2 Sumatriptan Dissolving Microneedle Iontophoretic Device Design
The in vitro results for P3 formulated microneedles, combined with iontophoresis, showed
a steady-state drug flux of 490 μg/cm2 over four hours with no lag time. Theoretically, an
iontophoretic microneedle device with surface area 8.7 cm2, electrical current of 500
μA/cm2 and 47.3 mg sumatriptan would provide a therapeutic plasma concentration over a
4-hour period. This iontophoretic microneedle patch would be more efficient and require
1/3 of the API when compared to the P1 formulated microneedle patch (Section 3.5.1).
An iontophoretic microneedle device would require a cathode patch, anode patch
over the microneedle, and power source. A low voltage positive (+) current would be
applied to the anode patch affixed above the dissolving microneedle. The current would
travel through the microneedle, into the skin to the cathode patch situated in adjacent
position on the skin. The power source would be programmed to apply current over the 4
hour application period. The power source system including the anode and cathode patches
could be designed as either a single-use or multiple use system. For a multiple-use system,
a new microneedle system would be applied to patch prior to each use.
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CHAPTER 4
MATHEMATICAL MODELLING FOR THE IN VITRO RELEASE OF
SUMATRIPTAN SUCCINATE FROM DISSOLVING MICRONEEDLE
SYSTEMS
4.1

Development of Mathematical Model for the In vitro Dissolution and Release of
Sumatriptan From Dissolving Microneedle Arrays

A mathematical model was derived to simulate the in vitro dissolution and release of drug
from dissolving, pyramid-shaped polyvinylpyrrolidone-based microneedle systems, as
previously described [49]. Simulation studies will aid in the evaluation and prediction of
critical microarray design properties (e.g., drug loading, needle height and needle pitchwidth) on transdermal drug delivery through the skin. The developed framework was
validated using in vitro data from polyvinylpyrrolidone-based dissolving microneedles
containing encapsulated sumatriptan succinate API described in Section 3.3.
Previous modeling research on microneedle systems has focused primarily on the
optimization of drug delivery from solid and hollow microneedle devices. In 2004, Davis
et al. developed a model for predicting the insertion and fracture forces of hollow
microneedle systems from specific geometric parameters (e.g, needle tip radius, wall
thickness, and wall angle) [43]. Later, Al-Qallaf et al. (2008) successfully developed a
mathematical framework for predicting the optimum design parameters (e.g., number of
needles, needle radius, pitch-width, etc) for the transdermal delivery of macromolecules
from solid and hollow microneedle systems [44]. These studies were followed by the
derivation of several diffusion models for solid [74] and hollow microarray devices [75,
76]. However, these governing equations do not include dissolution of the microneedle
and, therefore, cannot be used to assess the performance of soluble microneedle patches.
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A mathematical framework was developed by Kim et al. (2015) to describe the
dissolution and release of an encapsulated active ingredient from a single cone-shaped
microarray into a control volume. A set of equations were derived from the Nernst-Brunner
equation for the dissolution of the microneedle and drug concentration profiles in the skin.
The model was applied to simulate the release of fentanyl citrate from a single dissolving
sucrose microneedle. It was possible to determine the effects of the fentanyl mass fraction
and pitch width on transdermal delivery [77]. This research builds on this previous
contribution by deriving a set of governing equations for the delivery of the API from a
dissolving, pyramid-shaped microneedle into a control volume. In-silico modeling studies
will help to evaluate and predict the influence of critical design parameters (drug load,
polymer concentration, pitch width and needle height) on the release profile.
The mechanistic model described in this study is developed to capture the
dissolution process immediately after insertion of the array into skin. In this study, the
micron-sized needles are assumed to penetrate the epidermis but not the blood capillaries
and nerves in the dermis. The microneedle system is comprised of a biocompatible, watersoluble polymer matrix encapsulating water-soluble drug molecules. Once inside the skin,
the microarray is ‘wetted’ by the interstitial fluid, which allows the needles to quickly
dissolve to release the drug. The dissolved drug accumulate in the epidermis, diffuses
through the dermal layers and are absorbed into the systemic circulation.
The model was constructed by considering a rectangular control-volume
encompassing a single pyramid-shaped needle (Figure 4.1). This control-volume
represented the skin layer and was designed with a height equal to the skin depth, δS; length
on each side equal to the pitch-width, pw; and rectangular volume, v. The pyramid-shaped
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needle was fully submerged into the skin (i.e., rectangular control-volume) with initial
volume, vc,0; side length, L; and height, h. The mathematical model considered a number
of assumptions, including:
•

One-dimensional drug transport in the negative z-direction.

•

Drug metabolism in the skin is not considered.

•

Drug binding to viable skin tissues is not considered.

•

Mass transport through sides of control-volume is not considered.

•

Impact of needle properties on insertion into skin was not considered.

•

Decrease in needle volume directly correlates to increase in available skin layer
volume.

•

Microneedles and skin layer tissues are isotropic and dissolution occurs evenly
over surfaces of needle.

•

The API concentration in the skin is uniform (i.e, rate of diffusion is rapid
compared to rate of dissolution).
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Figure 4.1 Drug release from dissolving pyramid-shaped microneedle with base-plate.
For the purpose of the model, the drug particles are transported in the negative zdirection towards the base of the rectangular volume (i.e., systemic circulation). The
influence of various needles properties (i.e., needle height, pitch-width, base length) on
microneedles ability to penetrate the stratum corneum and fully insert into the skin were
not considered in this study. The model assumes individual needles fully insert into the
skin for transdermal delivery of drug. In vitro experiments with blue dye (nitrazine yellow)
demonstrated that circular microneedle arrays (N = 600) containing pyramid-shaped
needles (h = 0.05cm, l = 0.03cm) properly insert into the skin (Section 3.2) [42].
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The dimension of the control-volume was assumed to remain constant throughout
the dissolution process. The needle volume, vc, slowly decreases as it dissolves causing a
similar increase in the volume of the skin layer, v. The microneedles and skin layer tissues
are considered to be isotropic with the dissolution occurring evenly over the pyramid
needle surfaces. This assumption is valid if the drug substance and polymer concentration
are distributed homogenously throughout the pyramid needle. This leads to a constant half
angle at the apex of the pyramid throughout the dissolution of the microneedle. The half
angle is defined as the ratio of the pyramid needle height to the pyramid base length and is
defined by Equation 4.1 and depicted in Figure 4.2b.

tan  =

L(t ) L0
=
2h(t ) 2h0

(4.1)

Figure 4.2 Schematic of pyramid-shaped needle; (A) cross-section view; (B) half angle
view.
The concentration of active drug in the skin layer tissue was assumed to be uniform
throughout the compartment. This is a realistic assumption because diffusion was faster
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than the dissolution of the pyramid needles or the elimination of drug into systemic
circulation.
The mathematical model for describing the dissolution of the microneedle is
presented with the full derivations in Sections 4.1.1 and 4.1.2. The definition of the model
parameters are provided in Table 4.1. The material balance for drug mass in the skin layer
results in

 k tan   2   − c  
 1−   
dc(t )
= − ( kL c ) + 4  D
h 
 cS − 
 c(t ) 

dt

cos


+

−



  0 c,0 c  

 

(4.2)

The height of the pyramid is defined as

kD
dh(t )
=−
dt
 sin 



1 −  
c(t ) 
cS − 

  



(4.3)

The initial conditions are
c(t = 0) = 0

(4.4)

h (t = 0) = h0

(4.5)

and

The cumulative amount of drug released is

Q(t ) =  C ,0 − ( C (t) + c(t)( 0 +  C ,0 -  C (t)))

(4.6)

Additional equations were derived to describe the long-term release of drug from
dissolving microneedles containing a rectangular base-plate. The in vitro tests used to
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validate the mathematical model were generated from dissolving microneedles containing
a base-plate with uniform homogenous encapsulated PVP polymer and sumatriptan
succinate drug. The base-plate equations were simplified with the following assumptions:

•

The microneedle base-plate dissolves after the pyramid-shaped needles.

•

The ratio of parallelepiped sides remain constant during the dissolution.

The following equations were derived to describe the dissolution of the base-plate
following microneedle dissolution. The derivation of the equations is contained in Section
4.1.3 and the equation parameters are listed in Table 4.1. The drug concentration in the
solid baseplate, cSD, is described by
2

dcSD
k  A0 cs  d s pw2 cSD  3
= - D


dt
d s pw2
 M0 

(4.7)

cSD (0) = cSD,0

(4.8)

The drug concentration in the skin layer, c(t), after base-plate begins to dissolve, is
given by
2

k  A0 cs  d s pw2 cSD  3
dc
= - D

 − kLc
dt
d s pw2
 M0 

(4.9)

c(0) = cL

(4.10)
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The cumulative amount of drug released is

Q(t ) = ( C ,0 +m0 ) - ds pw2 (cSD (t) + c(t))

(4.11)

Immediately after the microneedle dissolves, the solid base-plate concentration, cSD, and
skin layer concentration, c, are zero and c(tD), respectively. The cumulative percent drug
released, M(t), is obtained by dividing Q(t) by  C ,0 +m0 .

M (t ) = 1 −

d s pw2 (cSD (t) + c(t ))
(  C ,0 + m0 )
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(4.12)

7
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4.1.1 Derivation of Dissolution Governing Equation for Microneedle Height
The derivation of the governing equation for the height of the microneedle begins with
defining the mass of an individual pyramid-shaped microneedle, with density, ρ; pyramid
base length, L; needle height, h; half angle, θ; and volume, vc.

1

 vc ( t ) =   L2 (t )h ( t ) 
3


(4.13)

Substitute Equation 4.1 to define mass of microneedle in terms of microneedle
height yields
4
3




 vc ( t ) =   h3 ( t ) tan 2  
(4.14)

Taking the first derivative with respect to time results in
dvc
dh
= 4h2 ( t ) tan 2 
dt
dt

(4.15)

A cross-section of a pyramid needle is depicted by Figure 4.2a with height from z
to z + Δz and side width, s. At zero time, the circumference of the pyramid needle is 4s
with each side having width

s=

L(l − h)
h

(4.16)

At time t + Δt, the outer layer pyramid dissolves by a thickness of Δɗ pictured in
Figure 4.1b and is used to defined the reduction of the pyramid base width, ΔW.
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W =

N
cos 

(4.17)

Thus, at time t + Δt the change in volume of the pyramid needle, due to dissolution,
is
h

vc = −  (4s)Wdz

(4.18)

0

Equation 4.18 is simplified with Equations 4.16 and 4.17 to yield
 L(h − z )  N
vc = −4 

h
 cos 
0
h


dz


(4.19)

Division of both sides of Equation 4.19 by Δt, taking the limit as Δt → 0, and
integrating produces
dvc
dN
= −2hL sec 
dt
dt

(4.20)

In Equation 4.20, the last term is determined from the Nerst and Brunner equation
[78]; with dissolution constant, kD, solubility of PVP in the body fluid, cS, and the mass
fraction of drug in the microneedle, β.
1 −   
dn k D 
=
cS − 
 c
dt
 
   

(4.21)

The Equation 4.20 and Equation 4.21 resulted in

k 
1 −    
dvc
= −2hL sec   D cS − 
 c
dt
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(4.22)

Finally, the right-hand side of Equations 4.15 and 4.22 yields the governing equation
for the height of the pyramid needle over time and initial condition:

kD
dh
=−
dt
 sin 


1 −   
cS − 
 c
   


h(0) = h0

(4.23)

(4.24)

4.1.2 Derivation of Dissolution Governing Equation for Skin Layer Drug
Concentration
It is necessary to first determine the volume of the compartment (i.e., skin layer), v(t), at
time t. The skin layer volume consists of the initial volume of the skin layer, v0, and the
volume gained as the microneedle dissolves in the tissue, vc,0 - vc (t). Here, vc,0 represents
the initial microneedle volume at zero time and vc(t) is the microneedle volume at time t.
Thus, the skin layer volume is
v(t ) = v0 + ( vc,0 − vc (t ) )

(4.25)

A mass balance on the skin layer control volume demonstrates the accumulation of
drug substance in the skin layer, d (vc) , is the difference between the drug released from
dt

the dissolving microneedle, − ( (kL d s )cz =d

s

)p

2

w

, and the drug exiting the skin layer into

 dvc 
.
 dt 

the bloodstream,   −

d (vc)
 dv 
= − (kL d s )cz =ds pw2 +   − c 
dt
 dt 

(

)
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(4.26)

The equations are simplified by applying the following chain rule (Equation 4.27)
d (vc)
dc
dv
=v
+c
dt
dt
dt

(4.27)

After combining Equations 4.27 and 4.26, the following equation is obtained:

v

dc
 dv 
= −(kL c)d s pw2 + (  − c)  − c 
dt
 dt 

(4.28)

Finally, both sides of Equation 4.28 are divided by v to give

 k tan   2   − c  
 1−   
dc
= − ( kL c ) + 4  D
h
c
−



S

 c

dt
  cos    0 + c,0 − c  
   

(4.29)

The initial condition is
c(0) = 0

(4.30)

4.1.3 Derivation of the Dissolution Equation for Drug Release From the
Microneedle Base-plate
The derivation of the governing equation for the base-plate of the microneedle begins with
defining the mass of the parallelepiped (Figure 4.1); with mass of drug remaining in
parallelepiped, M; mass transfer coefficient, kD; parallelepiped ‘wet’ surface area, A;
solubility of matrix polymer in solvent, CS; and concentration of drug in liquid phase, c.
dM
= −k  A(CS − Caq )
dt

(4.31)

The Equation 4.31 was simplified by assuming Caq << CS for most in vitro
situations to give
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dM
= −k  ACS
dt

(4.32)

Since the density remains constant during dissolution, it can be shown that:
2

 M 3
A = A0 

 M0 

(4.33)

Equation 4.32 is simplified to yield
2

 M 3
dM
= −k  A0CS 

dt
 M0 

(4.34)

M (0) = M 0

(4.35)

with the initial condition

As a results, we have the following system:
2

dcSD
dt

k D  A0 cs  d s pw2 cSD  3
= 

d s pw2
 M0 

cSD (0) = cSD,0

(4.36)

(4.37)

2

k  A0 cs  d s pw2 cSD  3
dc
= - D

 − kLc
dt
d s pw2
 M0 

(4.38)

c(0) = cL

(4.39)
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4.2

In vitro Release Studies for Validation of Sumatriptan Microneedle Dissolution
Mathematical Model

The dissolution mathematical model (Section 4.1) was analyzed using in vitro data from
pyramid-shaped dissolving sumatriptan microneedles to estimate dissolution and
elimination rate constants. The predicted drug release profile was validated against in vitro
data for three separate sumatriptan microneedle formulations. Simulation experiments to
evaluate key design parameters (drug load, polymer concentration, needle height and pitch
width) for release of sumatriptan succinate from dissolving pyramid-shaped microneedles
[49].
4.2.1 Comparison of Simulated and Experimental In vitro Minipig Results
The dissolution model for predicting drug release from dissolving pyramid-shaped
microneedles was evaluated against in vitro data from dissolving microneedles containing
the base-plate and formulated to release the sumatriptan succinate. Equation 4.12 was used
to predict the drug release profiles of three different sumatriptan formulations (P1, P2, and
P3) with different drug loading and polymer concentration (Table 2.1). The microneedle
dimensions and formulation parameters were determined by experiments in the lab
(Section 3.2) and are summarized in Table 3.1. Regression techniques, implemented in
Mathematica®, were applied to the in vitro data for all formulations to derive estimates for
the dissolution rate constants, kD, and elimination rate constants, kL. The standard weighted
squared error between simulated values from Equation 4.12 and in vitro results was
minimized with respect to kL and kD (Table 4.2). The predicted kD and kL values were used
to generate theoretical release profile which compared well with the experimental results,
see Figures 4.3 – 4.5.

87

Table 4.2 Estimated Sumatriptan Microneedle Formulation Parameters for Dissolution
Model
tD1*
(h)

kD*
(cm/h)

kL*
(h-1)

P1

1.28 ± 0.6

0.0143 ± 0.0074

0.0516 ± 0.0030

P2

0.51 ± 0.6

0.0388 ± 0.055

0.0569 ± 0.0052

P3

0.23 ± 0.2

0.0912 ± 0.088

0.0621 ± 0.0016

Formulation
Circle Arrays

*value ± confidence interval

Figure 4.3 Plots comparing minipig in vitro cumulative percent release of P1
microneedles (solid dots) to predicted profiles (solid lines).
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Figure 4.4 Plots comparing minipig in vitro cumulative percent release of P2
microneedles (solid dots) to predicted profiles (solid lines).

Figure 4.5 Plots comparing minipig in vitro cumulative percent release of P3
microneedles (solid dots) to predicted profiles (solid lines).

89

Figure 4.6 In vitro percent release sumatriptan succinate from dissolving microneedle
after 6 hours from formulation P1 (●), P2 (■) and P3(♦); average values (n = 3).
Estimated dissolution times for microneedles from each formulation were
generated using the model and predicted kD and kL values (Table 4.2). The dissolution time
for the P1 formulation (13.8 min) was similar to dissolution times calculated observed
experimentally in the lab (< 15 minutes). Tomographic imaging studies conducted in the
lab showed P1 formulated dissolving microarrays with circle geometry dissolving in
approximately 10 minutes (Section 3.2). Similar experimental results related to dissolution
of PVP-based microneedles in porcine skin were reported by both Sullivan and Quin [79,
80]. The P1 and P2 formulations, on the other hand, demonstrated significantly higher
dissolution times of 30.6 and 76.8 minutes, respectively. However, it should be noted that
the confidence intervals were very high for all three formulations.
The estimated dissolution rate constant values correlated to experimental results
with a similar trend of kD [P1] < kD [P2] < kD [P3] as shown in Figure 4.6, where kD [Pi]
represents the Pi formulation value. A higher initial release is realized as the process is
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governed by dissolution at early times. This behavior is predicted by Equation 4.9 for the
accumulation of drug in the skin layer which indicates slow first-order clearance into the
blood stream (first term on right-hand side) as compared to dissolution term (second term
on right-hand side).
The relationships between the P1 – P3 microneedle formulation parameters
(polymer conc., drug load and density) with the dissolution and elimination rates are not
completely understood and require subsequent investigations. No trends were observed
when comparing the drug load, β, to the kD results. The density of the microneedle
formulations increased in a similar manner to the kD values: ρ [P1] < ρ [P2] < ρ [P3].
Further investigation is required to determine if drug release from microneedles can be
altered by the density. A 10 % increase in PVP polymer matrix concentration from P3 to
P2 related to a 42.5 % reduction in the kD value. A similar increase in drug release with
decreased polyvinylpyrrolidone concentration in dissolving microneedles was observed by
Shah et al. [81]. On the other hand, the elimination rates remained constant with all three
formulations, kL [P1] < kL [P2] < kL [P3].
4.2.2 Simulation Studies
Simulation studies were conducted to determine optimal design parameter values for the
sumatriptan succinate dissolving microneedle systems. The impact of changing the
microneedle height, microneedle pitch-width or loading dose on drug delivery, was
evaluated. The simulations were performed using the P1 microneedle formulation
parameters.
The response to varying the initial microneedle height, h0, was assessed by plotting
skin layer concentration, c(t), as a function of time for three h0 values (Figure 4.7). The
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initial height of the pyramid needles had a major effect on drug release as indicated by cmax
values. For example, a 20% increase in height from 0.05 cm to 0.06 resulted in 69%
increase in cmax values from 0.036 μg/ml to 0.061 μg/ml.
The influence of pitch width, pw, on drug delivery was evaluated by plotting skin
layer concentration, c(t), as a function of height for three pw values (Figure 4.8). The pitch
width had a significant impact on skin layer concentration as a negligible increase in pitch
width related to a considerable reduction in drug concentration. For example, a 50%
increase in pitch width from 0.035 cm to 0.0525 cm resulted in a 44% decrease in drug
concentration from 0.017 μg/ml to 0.0075 μg/ml.
The effect of drug loading, β, was measured by plotting skin layer concentration,
c(t), as a function of height for three β values (Figure 4.9). The sumatriptan concentration
in the microneedles had a direct relationship with the drug layer concentration. Incremental
variations in microneedle sumatriptan concentration led to proportional changes in drug
layer concentration. For example, decreasing the sumatriptan content in microneedle threefold from β = 0.3 to β = 0.1 produced a three-fold decrease in skin concentration from
0.017 μg/ml to 0.051 μg/ml.
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Figure 4.7 Modelling effect of needle height on sumatriptan succinate release using P1
formulation parameters; needle height, h [h = 0.06cm (̶ •), h = 0.1 (—), h = 0.1(--)].

Figure 4.8 Modelling effects of pitch width on sumatriptan succinate release using P1
formulation parameters; pitch width, pw, of microneedle [pw = 0.035cm (--),
pw = 0.0525cm (—), pw = 0.07cm ( ̶ •)].
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Figure 4.9 Modelling effects of drug loading on sumatriptan succinate release using P1
formulation parameters; mass fraction (β) sumatriptan succinate in microneedle
[β = 0.1% ( ̶ •), β = 0.2% (—), β = 0.3% (--)].

4.3

Development of Mathematical Model for In vitro Dissolution, Diffusion and
Release of Drug Substance From Dissolving Microneedle Array

In this section, a mathematical model, which includes the dissolution and diffusion, is
introduced to predict drug release from a dissolving pyramid-shaped microneedle. The
previous model, developed in Section 4.1 and described in [49], estimated the percentage
of drug released from dissolving microneedles using equations for microneedle height
(Equation 4.3) and skin layer concentration (Equation 4.2). Note that the simplified model
assumed a constant homogenous drug concentration in the skin layer. In this study, a new
model is developed by applying Fick’s second law of diffusion and a material balance on
the drug in the skin. This approach will be used to predict the drug concentration profile
within the epidermis over time during and after dissolution of the microneedle.
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The dissolution and diffusion equations were developed using a method similar to
the homogenous model described in Section 4.1. The microneedle depicted in Figure 4.1
is used again to derive the equations. In this case, the assumptions made in generating the
model are listed below:
•

One-dimensional drug transport in the negative z-direction.

•

Drug metabolism in the skin is not considered.

•

Drug binding to viable skin tissues is not considered.

•

Mass transport through sides of control-volume not considered.

•

Impact of needle properties on insertion into skin was not considered.

•

Decrease in needle volume directly correlates to increase in available skin layer
volume.

•

Microneedles and skin layer tissues are isotropic and dissolution occurs evenly
over surfaces of needle.
A dissolution and diffusion model is described by the set of equations listed below

and includes the governing equation for change in microneedle height and the change in
skin layer drug concentration. A complete derivation of the governing equations for
microneedle height and skin layer concentration are included in Sections 4.1.1 and 4.1.2,
respectively. All parameter definitions are presented Table 4.1.
The material balance for drug mass in the skin layer is,
 k tan 
c
 2c
= D 2 + 4 D
t
z
  cos

 2
 − c
 h 
  v0 + vc,0 − vc

The height of the pyramid is defined as
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k c
dh(t )
=− D S
dt
 sin 

(4.41)

h ( 0) = h0

(4.42)

c ( x,0) = 0

(4.43)

The initial conditions are

and

It is assumed that the concentration at the boundary plane between the pyramid base
and the baseplate remains unchanged while the microneedle dissolves,

c ( z, t )
=0
z z =0

(4.44)

The drug concentration at the base of the control-volume (ie. blood stream)
maintains sink conditions:

c ( ds , t ) = 0

(4.45)

Thus, diffusive flux, J(t), through the base of the control-volume (i.e., blood
stream) is defined as

J ( t ) = − pw2 D

c ( z, t )
z z =d
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(4.46)
s

The cumulative amount of drug released Q ( t ) is then determined from the
diffusive flux, (J(t),

Q ( t ) =  J ( ) d
t

0

(4.47)

The cumulative percent drug released, M(t), is obtained by dividing Q(t) by

 C ,0 +m0 .

 J ( ) d
t

M (t ) =

0

( 

c ,0 + m0 )

(4.48)

In a second step, the dissolution and diffusion model equations were revised to
describe the long-term release of drug from dissolving microneedles containing a
rectangular base-plate. In vitro tests used to validate the model equations for release and
diffusion of dissolving microneedles containing a rectangular base-plate with uniform
homogenous encapsulated PVP polymer and sumatriptan succinate drug. The base-plate
equations were developed with similar assumptions to the previous base-plate equations
for the dissolution model (Equations 4.7 to 4.10):
•

The microneedle base-plate dissolves after the pyramid-shaped microneedles.

•

The ratios of parallelepiped sides remain constant during the dissolution.

In modeling the drug release from the microneedle and base-plate, the previous
governing equations (Equations 4.40 - 4.45) are combined with the a new pyramid base
boundary condition (Equation 4.49). Several conditions are applied to Equation 4.49 with
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t=

h0  sin ( )
d p2 c
describing the time it takes for microneedle to dissolve; t = s w S 0
cs kd
kd  A0cs

defining the dissolution time of the base-plate alone.

pw2 D

4.4

c ( z, t )
z z =d

s


0



= −kd  A0cs



0


t

h0  sin ( )
cs kd

h0  sin ( )
h  sin ( )
d p2 c
 t  s w S0 + 0
(4.49)
cs kd
kd  A0cs
cs kd
t

d s pw2 cS 0 h0  sin ( )
+
kd  A0 cs
cs kd

In vitro Release Studies for Validation of Sumatriptan Microneedle Dissolution
and Diffusion Mathematical Model

Simulations, using the dissolution and diffusion mathematical model (Section 4.3) will be
run to evaluate the effects of key design parameters (drug load, polymer concentration,
needle height and pitch width) on the release of sumatriptan succinate from microneedles.
Later, the model will be validated with in vitro data from pyramid-shaped sumatriptan
microneedle devices containing a rectangular base-plate.
4.4.1 Simulation Experiments
The P1 formulated circle microneedle arrays were used as a base-case with dimensions and
formulation parameters determined by laboratory experiments (Section 3.2) and
summarized in Table 3.1. The dissolution rate (kD = 0.0143 cm/h) for P1 formulation,
determined through regression techniques in Section 4.2, was applied. The diffusion
coefficient for sumatriptan succinate across Göttingen minipig skin (D) was approximated
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from the steady-state diffusion equation and the lag-time method [82]. A value of D = 7.90
x 10-5 cm2/h was determined.
Contour plots are shown in Figures 4.10 – 4.13 and demonstrate the influence of
drug load, pitch width and needle height on the drug concentration within the epidermis
after 4 hours. Changes in the load and pitch-width had a significant impact on drug
diffusion. Reducing the drug load 20%, from β = 21.42% to β = 17.14%, led to a 50%
decrease in sumatriptan concentration at base of skin compartment (Figure 4.11).
Decreasing pitch-width 20% , from pw = 0.035 cm to pw = 0.028 cm, led to a 100% increase
in drug content at the base of the control-volume (Figure 4.12). On the other hand, changes
in the microneedle height had a less pronounced effect with a 20% decrease in height, h,
from h = 0.05 cm to h = 0.04 cm, leading to a very negligible decrease in drug diffusion.
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Figure 4.10 Contour plot of sumatriptan drug release from P1 microneedle after 4 hours
[h = 0.05 cm, β = 21.42%, pw = 0.035 cm].
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Figure 4.11 Contour plot of sumatriptan drug release from P1 microneedle after 4 hours
with reduced mass fraction API [h = 0.05 cm, β = 17.14%, pw = 0.035 cm].
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Figure 4.12 Contour plot of sumatriptan drug release from P1 microneedle after 4 hours
with reduced pitch width [h = 0.05 cm, β = 21.42%, pw = 0.028 cm].
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Figure 4.13 Contour plot of sumatriptan drug release from P1 microneedle after 4 hours
with reduced microneedle height [h = 0.04 cm, β = 21.42%, pw = 0.035 cm].

4.4.2 Comparison of Simulated and Experimental In vitro Minipig Results
A comparison was conducted to evaluate the dissolution and diffusion model estimated
drug release profiles versus the in vitro data for the dissolving microarrays containing
encapsulated sumatriptan in microneedles and a base-plate. Equations 4.48 and 4.49 were
used to predict the drug release profiles of three different sumatriptan formulations (P1,
P2, and P3) with different drug loading and polymer concentration (Table 2.1). Both the
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microneedle dimensions and formulation properties were previously determined in lab
experiments (Section 3.2) and are summarized in Table 3.1. In vitro data was augmented
to include data from pull-points at 1, 2, 4, 6, 8, 24, 28 and 32 hours. Mathematica® software
was used to apply regression techniques to the in vitro data for prediction of dissolution
rate constant, kD; and diffusion coefficient, D. The standard weighted squared error
between simulated values from Equation 4.48 and in vitro results was minimized with
respect to kD and D (Table 4.3). The predicted kD and D values were used to generate
theoretical release profiles which compared extremely well with the experimental results
(Figures 4.14 – 4.16). Additionally, contour plots showing the diffusion gradient in the skin
layers after 4 hours are shown for each formulation (Figures 4.17 – 4.19).
The estimated diffusion coefficients for all three formulations showed the following
trend, D [P1] ≈ D [P3] > D [P1] (Table 4.3), where D [Pi] represents the Pi formulation
value. The 12 – 14% increase in D values for P1 and P2 indicates a possible inverse
relationship between the diffusion coefficient and formulation drug content. On the other
hand, dissolution rate constants for each of the formulations increased in the order of kD
[P2] < kD [P1] <<< kD [P3]. As expected, a similar trend was observed in relation to both
the microneedle dissolution times and the base-plate dissolution times. The P3 formulated
microneedles exhibited very rapid pyramid dissolution time (1.6 min) and base-plate
dissolution (0.2 min) compared to P1 and P2 microneedles (> 37 min). This demonstrates
that polymer content has a significant impact on dissolution with a 10% (w/w) reduction
in PVP concentration between preparations P1 and P2 versus P3 yielding over 26,000%
increase in kD. The drug loading had a much less significant role with 10% (w/w) increase
in sumatriptan between P2 and P1 only generating 38% increase in dissolution rate.
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Table 4.3 Estimated Sumatriptan Microneedle Formulation Parameters for Dissolution
and Diffusion Model
tD1*
(h)

tD2*
(h)

kD*
(cm/h)

P1

0.625 ± 0.28

1.65 ± 0.024

0.0264 ± 0.012

1.57 ± 1.3

P2

0.904 ± 0.19

2.00 ± 0.0045

0.0192 ± 0.0040

1.75 ± 0.81

P3

0.0265 ± 0.22

0.0034 ± NA

7.01 ± NA

1.79 ± 0.88

Formulation

(10-4

D*
cm2/h)

Circle Arrays

*Microneedle dissolution time, tD1; base-plate dissolution time, tD2; dissolution rate
constant, kD; diffusion coefficient, D; value ± confidence interval (NA refers to standard
deviation greater than 3 times the mean.

Figure 4.14 Plots comparing minipig in vitro cumulative percent release of P1
microneedles (solid dots) to predicted profiles (solid lines).
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Figure 4.15 Plots comparing minipig in vitro cumulative percent release of P2
microneedles (solid dots) to predicted profiles (solid lines).

Figure 4.16 Plots comparing minipig in vitro cumulative percent release of P3
microneedles (solid dots) to predicted profiles (solid lines).
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Figure 4.17 Contour plot of sumatriptan drug release from P1 microneedle after 4 hours.
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Figure 4.18 Contour plot of sumatriptan drug release from P2 microneedle after 4 hours.
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Figure 4.19 Contour plot of sumatriptan drug release from P3 microneedle after 4 hours.

4.5 Development of Mathematical Model for In vitro Dissolution, Diffusion, and
Release of Sumatriptan From Dissolving Microneedle Array Aided by Iontophoresis
Here, a mathematical framework, incorporating dissolution, diffusion and electromigration, is presented to estimate drug release from dissolving pyramid-shaped
microarrays under a low-density electric current. For this study, a new electrophoretic
transport model is derived by applying Ohm’s law of electro-migration, Fick’s second law
of diffusion, and a mass balance on the drug in the skin. This method will allow for
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researchers to predict how drug is transported during and after microneedle treatment
combined with iontophoresis.
The equations for dissolution, diffusion and electrophoretic transport of ionic drug
molecules were developed using the control-volume depicted in Figure 4.1. The model is
based on the following assumptions, listed below:
•

One-dimensional drug transport in the negative z-direction.

•

Drug metabolism in the skin is not considered.

•

Drug binding to viable skin tissues is not considered.

•

Mass transport through sides of control-volume not considered.

•

Impact of needle properties on insertion into skin was not considered.

•

Decrease in needle volume directly correlates to increase in available skin layer
volume.

•

Microneedles and skin layer tissues are isotropic and dissolution occurs evenly
over surfaces of needle.

•

Electrical current is applied through an anode electrode placed above the
microneedle array after insertion into the skin (Figure 1.3).

The developed equations are listed below and includes changes in the microneedle
height and in the skin layer drug concentration. The detailed derivation provided in
Sections 4.1.1 and 4.5.1. All of the equation parameters are listed in Table 4.1.
The material balance for drug mass in the skin layer is given by Equation 4.50;
where γ is a dimensionless electromigration/convection parameter which represents the
influence of the current applied to the microneedle and skin.
 k tan   2 
c
 2c  D C
 − c
=D 2 −
+ 4 D
 h 
t
 S x
z
  cos   v0 + vc,0 − vc
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The height of the pyramid is defined as

kc
dh(t )
=− d S
dt
 sin 

(4.51)

h ( 0) = h0

(4.52)

c ( x,0) = 0

(4.53)

The initial conditions are

and

The drug concentration at the base of the control-volume (ie. blood stream):

c ( ds , t ) = 0

(4.54)

Therefore, diffusive flux, J(t), through the base of the control-volume (i.e., blood
stream) is defined as

J ( t ) = − pw2 D

c ( z, t )
z z =d

(4.55)
s

The cumulative amount of drug released Q ( t ) is then determined from the
diffusive flux, (J(t),

Q ( t ) =  J ( ) d
t

0
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(4.56)

The cumulative percent drug released, M(t), is obtained by dividing Q(t) by

 C ,0 +m0 .

 J ( ) d
t

M (t ) =

0

( 

c ,0

(4.57)

+ m0 )

4.5.1 Derivation of Electrophoretic Transport Governing Equations for Skin Layer
Concentration
The iontophoretic transport equation for ionic compounds through the skin is given by
Equation 4.58 which defines the concentration of drug in the skin layer as the result of
passive diffusion, electro-migration, and convection [83-85].

c
 2c  D c c
=D 2 −
−
t
z  S x x

(4.58)

Where υ is the convective flow velocity in the viable skin, and ν is an iontophoretic
model parameter defined as  =

zFE
; z is the ionized drug charge; F is the Faraday
RT

constant; E is the electric field; R is the ideal gas constant; and T is the temperature.
Equation 4.58 is simplified by substituting the model parameter  =

D
+  , which
S

accounts for electro-migration and convection processes. However, at relatively low fluid
velocities the convection processes are negligible (i.e.,  =

c
 2c  D c
=D 2 +
t
z  S x
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D
), yielding Equation 4.59,
S

(4.59)

Therefore, drug accumulation in the control-volume, d (vc) ; is the result of passive
dt

 D c
 2c
diffusion D 2 ; the electro-migration of drug into the skin,
; and its elimination
 S x
z



into the systemic circulation (Section 4.1.2), 4  kD tan   h2   − c  cs −  1 −   c 
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Simulation Studies to Evaluate Sumatriptan Microneedle Dissolution,
Diffusion, and Electro-migration Mathematical Model

Computer simulations were conducted with the dissolution, diffusion, and electromigration transport model (Section 4.5) to determine the effect of electrical current (i.e.,
parameter γ) on the release of sumatriptan succinate from dissolving pyramid-shaped
microneedles. The study uses the P1 circle microarray system dimensions and formulation
parameters that were determined previously in Section 3.2 and summarized in Table 3.1.
In vitro minipig release data were used to determine the dissolution rate (kD = 0.0143 cm/h)
by applying regression techniques described in Section 4.2. Also, release values were used
to estimate the diffusion coefficient (7.901 x 10-5 cm2/h) from the steady-state diffusion
equation for lag time, tlag =h2/6D [82]. The electromigration/convection parameter, γ, was
approximated to be 0.8 based on reference data for similar iontophoretic in vitro
experiments applied to the drug amitriptyline HCL [84, 86].
Equation 4.66 was used to predict the in vitro drug release profiles of P1 formulated
microarray patches under varied electrical current (Figure 4.19). The γ parameter correlates
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to the influence of current on the drug transport with increased γ values related to increased
current levels [84]. The study showed a favorable increase in percent sumatriptan released
through the skin. A γ value of 1.6 related to an estimated 42% drug released after 8 hours,
as compared to approximately 34% with no applied current.

Figure 4.20 Predicted effect of the iontophoretic parameter, γ, on in vitro cumulative
percent sumatriptan released from P1 microneedles over an 8 hour period; γ = 0 (solid);
γ = 0.8 (dashed); and γ = 1.6 (dot-dashed).
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CHAPTER 5
CONCLUSION

This research involves a dissolving polyvinylpyrrolidone-based microneedle device
designed for the transdermal delivery of sumatriptan succinate for migraine relief. The
product is a suitable alternative drug delivery method that is painless and with minimal
unwanted side effects. The microneedle systems were fabricated from a 0.785-cm2 circular
array with 600 pyramid-shaped needles with consistent height (500 µm), width (300 µm),
and pitch (350 µm). Three formulations (P1, P2, P3) were successfully prepared from 5 –
10% (w/w) sumatriptan succinate API, 20 – 30% (w/w) polyvinylpyrrolidone, polysorbate
80, glycerol and purified water. Tensile tests showed that the microarray strength was
improved by increasing polyvinylpyrrolidone concentration or decreasing the sumatriptan
load. In vitro experiments were carried out on female Göttingen minipig skins with and
without iontophoresis (i.e., low electrical current). Microneedles from each formulation
properly inserted into the minipig skin as observed with optical microscope and visual
inspection with indicator solution (Nitrazine yellow dye). Transepidermal water loss
(TEWL) studies performed pre-and post- microneedle treatment demonstrated a 4.9-fold
reduction in the barrier function. This change was greater than the 4.6-fold decrease
observed following removal of the stratum corneum by tape-stripping (15x). These TEWL
results indicate the microarrays produce an array of low-resistance tunnels which facilitate
transport of water through the stratum corneum. In vitro release studies showed a major
decrease in the lag time and an increased steady-state flux compared to previously
developed sumatriptan transdermal delivery systems. Additional iontophoretic in vitro
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experiments were conducted on each of the three microneedle formulations using a small
electrical current of 100 – 500 µA/cm2. The electrical current significantly increased the
flux of sumatriptan across the skin with only one third of the API required to deliver a
similar therapeutic dose as that of a microneedle device alone.
The design of new dissolving microneedle systems will require additional experimental
design work and in vitro studies to optimize the microneedle geometry and formulation
parameters. Model-based design was selected in this contribution as an efficient approach
to assist researchers in the design and optimization of microneedle systems for drug
delivery of macromolecules.
Initially, a mathematical model was derived to predict sumatriptan succinate delivery
from a pyramid-shaped microarray system. The model was applied to the three different
sumatriptan microarray formulations to estimate the cumulative amount of drug released
calculate the dissolution and elimination rate constants. It was concluded that increasing
the drug load led to a rise in the maximum drug concentration in the skin; increasing the
microneedle height resulted in a minor enhancement of drug layer concentration; and
increasing the pitch width significantly reduced the sumatriptan content in the epidermis.
Next, a second mathematical model was generated to describe the dissolution and diffusion
of the medication through the dermal layers. The platform was used to predict diffusion
profiles of the three sumatriptan formulations and estimate the diffusion coefficient and
dissolution rate constants. Computer simulations determined that the polyvinylpyrrolidone
concentration had a major impact on the microneedle dissolution. Reduction of the pitch
width greatly increased diffusion through the skin. Finally, mathematical equations were
derived to describe the dissolution and permeation of soluble microarrays and changes in
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the dermal drug concentration following the application of a low-density electric current.
Simulation studies showed that moderate improvement in the sumatriptan drug release
could be achieved by increasing the current density.
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